REVIEW

Open Access

Clinical features, hospitalisation and deaths associated with monkeypox: a systematic review and meta-analysis



Vicente A. Benites-Zapata¹, Juan R. Ulloque-Badaracco¹, Esteban A. Alarcon-Braga^{1,2}, Enrique A. Hernandez-Bustamante^{3,4}, Melany D. Mosquera-Rojas^{1,2}, D. Katterine Bonilla-Aldana^{5,6} and Alfonso J. Rodriguez-Morales^{5,6,7,8*}

Abstract

Introduction: A multicountry monkeypox disease (MPX) outbreak began in May 2022 in Europe, leading to the assessment as a potential Public Health Emergency of International Concern (PHEIC) on June 23, 2022. Some observational studies have partially characterised clinical features, hospitalisations, and deaths. However, no systematic reviews of this MPX outbreak have been published.

Methods: We performed a systematic review with meta-analysis, using five databases to assess clinical features, hospitalisations, complications and deaths of MPX confirmed or probable cases. Observational studies, case reports and case series, were included. We performed a random-effects model meta-analysis to calculate the pooled prevalence and 95% confidence interval (95% Cl). In addition, we carried out a subgroup analysis according to the continents and a sensitivity analysis excluding studies classified as having a high risk of bias.

Results: A total of 19 articles were included, using only 12 articles in the quantitative synthesis (meta-analysis). For 1958 patients, rash (93%, 95% CI 80–100%), fever (72%, 95% CI 30–99%), pruritus (65%, 95% CI 47–81%), and lymphadenopathy (62%, 47–76%), were the most prevalent manifestations. Among the patients, 35% (95% CI 14–59%) were hospitalised. Some 4% (95% CI 1–9%) of hospitalised patients had fatal outcomes (case fatality rate, CFR).

Conclusion: MPX is spreading rapidly, with a third of hospitalised patients, but less than 5% with fatal outcomes. As this zoonotic virus spreads globally, countries must urgently prepare human resources, infrastructure and facilities to treat patients according to the emerging guidelines and the most reliable clinical information.

Keywords: Monkeypox, Orthopoxvirus, Poxviridae, Zoonotic, Clinical features, Laboratory, Outcomes, Epidemic

Introduction

Rationale

Monkeypox virus (MPXV), an Orthopoxvirus, is a genus that includes the smallpox virus [1, 2]. This emerging zoonotic agent was discovered in 1958 in

*Correspondence: arodriguezmo@cientifica.edu.pe

 7 Master of Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima, Perú

causing human disease since 1970 in endemic countries in Africa [3–6]. This pathogen causes a two-clinical stage illness, including a prodrome during its invasive period and a cutaneous phase defined as the skin eruption [7]. Although described over decades, the current ongoing outbreak outside Africa seems to present atypical clinical manifestations compared to cases reported before 2022 in endemic countries [8–10]. The MPXV, taxonomically, is currently part of the genus

Denmark among laboratory monkeys but had been



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Full list of author information is available at the end of the article

Orthopoxvirus, which belongs to the subfamily Chordopoxvirinae in the family Poxviridae. That family is part of the order Chitovirales included in the class Pokkesviricetes. This class belongs to the phylum Nucleocytoviricota, in the kingdom Bamfordvirae, in the realm Varidnaviria [11–14].

Members of the genus Orthopoxvirus cause disease in humans and animals, as well as other members of the family Poxviridae affecting birds, goats, cervids, crocodiles, rabbits, and insects [6]. In the case of smallpox, this epidemic disease was eradicated by the 1980s after a successful global vaccination campaign. Since there, no vaccination against smallpox has continued [15]. As expected, several similarities and differences in the epidemiology, clinical features, and management of smallpox and monkeypox have been identified. These are enveloped double-stranded DNA viruses with a genome ranging from 130 to 300 kbp (around 190 kbp for monkeypox) [16]. Therefore, a complete clinical characterisation of MPX disease, as well as cutaneous lesions, hospitalisation and outcome, is required.

Although only two months have elapsed since the global spreading of MPX in 2022 [17], some studies and case reports have been already published in major international scientific and medical journals from European and other countries with travel- and non-travelrelated cases [8, 9, 18, 19]. Many of these reports have started to answer clinical questions, including evolution and outcomes, potential risk factors, and clinical, especially dermatological findings [20]; however, a systematic review consolidates what has been learned from each study or reported case is to date missing. Although systematic reviews and meta-analyses usually include randomised clinical trials (RCTs) and aim to provide a more precise estimate of the effect of a treatment or risk factor for disease, they also have been extensively used, especially during the last decades, to synthesised observational studies [21-23]. However, RCTs are not feasible or available in many situations, and only data from observational studies are accessible [23]. That is the case for the clinical, hospitalisation, and outcome features of MPX.

Objectives

- To summarise the clinical features of MPX reported in currently available observational studies.
- To assess the clinical spectrum of the cutaneous manifestations and their frequency.
- To examine the outcome of MPX cases, including the proportion of patients requiring hospitalisation and those with fatal outcomes.

Methods

Protocol and registration

This protocol follows the recommendations established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [24], and it has been reported in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42022336855).

Databases and search strategy

A comprehensive search about the prevalence of clinical manifestations, characteristics of the lesions and complications of patients diagnosed with monkeypox was conducted on June 7, 2022, through the following databases: PubMed, Scopus, Embase, Ovid-Medline and Web of Science. No restrictions regarding language or publication date were applied. The search strategy was built using the Peer Review of Electronic Search Strategies (PRESS) Checklist, and we carried out a hand search of the reference lists of the included studies and preprints databases (The Lancet Preprints, medRxiv and ResearchSquare). The complete search strategy is available in Additional file 1: Table S1.

Study selection and data extraction

This systematic review had a comprehensive scope, including the subsequent observational studies: crosssectional, cohort, case–control, case reports and case series. In addition, studies assessing the prevalence of the various clinical manifestations, characteristics of the lesions and complications of patients with a probable or confirmed monkeypox diagnosis, regardless of age, were included. The definitions of possible and confirmed cases for each study are described in Additional file 1: Table S2. Case series with more than 10 cases were included in the qualitative and quantitative synthesis; however, studies with less than ten were included only in the qualitative synthesis. Scoping reviews, narrative reviews, systematic reviews and conference abstracts were excluded.

All the articles resulting from the electronic search were exported to the data management software "Rayyan QCRI", and duplicate records were removed. Titles and abstracts were independently screened by four reviewers (JRU-B, EAA-B, MDM-R and EAH-B). After identifying the potential references to be included, the reviewers independently assessed the full text of each article. Conflicts or discrepancies in decisions were resolved through debate among the total of the authors, then a consensus was reached. The data from the included articles were extracted through a data extraction sheet built in Microsoft Excel. The following information was extracted: author, year of publication, and the number of probable

Author	Country	Year	Participants(male/ female)	Median/mean /range age (IQR/SD)	Classification of the cases presented	Smallpox vaccination history (includes visible smallpox scar)
Formenty et al.	Sudan	2010	19 (9/10)	8 months-32 years	Confirmed cases: 10 Prob- able cases: 9	ЛR
Huhn et al.	USA	2005	34 (18/16)	26 (6–47)	All patients are confirmed cases	7/34
Yinka-Ogunleye et al.	Nigeria	2019	122 (84/38)	29 (2 days old-50 y),	Confirmed cases: 118 Probable cases: 4	NR
Whitehouse et al.	Democratic Republic of Congo	2021	1057 (568/469)	14 (6–23.9)	All patients are confirmed cases	97/1057
Ježek et al.	Democratic Republic of Congo	1988	338 (182/156)	3 months-69 years	All patients are confirmed cases	43/338
Kalthan et al.	Central African Republic	2016	12 (6/6)	31.6 (12.37)	Confirmed cases:4 Prob- able cases:8	NR
Pittman et al.	Democratic Republic of Congo	2022	216 (138/78)	14 (9.9)	All patients are confirmed cases	4/216
Breman et al.	Central and West Africa (5 countries)	1980	47 (21/26)	8 years (7 months-35 years)	Confirmed cases:35, Prob- able cases:12	4/47
Perez-Duque et al.	Portugal	2022	27 (27/0)	33 (22–59)	All patients are confirmed cases	1/27
Learned et al.	Democratic Republic of Congo	2003	11 (8/3)	9.6 (7.3)	Confirmed cases:3, Prob- able cases:8	0/11
Mande et al.	Democratic Republic of Congo	2022	21 (14/7)	16 (4–30)	All patients are confirmed cases	NR
Girometti et al.	United Kingdom	2022	54 (54/0)	41 (34-45)	All patients are confirmed cases	NR
Vaughan et.al	United Kingdom	2018	2 (2/0)	NR	All patients are confirmed cases	NR
Antinori et al.	Italy	2022	4 (4/0)	NR	All patients are confirmed cases	1/4
Hammerschlag et al.	Australia	2022	1 (1/0)	NR	Confirmed Case	NR
De Nicolas-Ruanes et al.	Spain	2022	1 (1/0)	30	Confirmed Case	NR
Reynolds et al.	Sierra Leone	2019	1 (1/0)	35	Confirmed Case	NR
Erez et al.	Israel	2019	1 (1/0)	NR	Confirmed Case	NR
Adler et al.	United Kingdom	2022	7 (4/3)	NR	All patients are confirmed cases	NR

 Table 1
 Characteristics and main clinical manifestations of the included studies

ble 1 (cont	nical nifestations	
cinued)		

(affected patients/ total patients)														
Lymphadenopathy	Photophobia	Myalgias	Fever	Arthralgia	Pruritus	Conjunctivitis	Rash	Diarrhoea	Cough	Headache	Fatigue	Sore throat	Difficulty breathing	Naus
15/19	NR	15/19	16/19	15/19	NR	11/19	19/19	2/9	10/19	11/19	12/19	NR	12/19	2/19
19/34	NR	19/34	28/34	2/34	NR	3/34	32/34	2/34	16/34	22/34	NR	21/34	6/34	11/34
45/65	NR	42/67	81/92	NR	57/78	NR	122/122	NR	NR	61/77	NR	45/77	NR	NR
876/1034	332/999	754/1003	1023/1057	NR	542/1012	210/1016	1057/1057	NR	561/1024	793/1011	888/1029	246/325	NR	250/1
163/295	NR	NR	NR	NR	NR	NR	295/295	NR	100/280	NR	NR	NR	NR	NR
6/12	NR	NR	11/12	NR	NR	NR	12/12	NR	NR	2/12	NR	NR	NR	NR
213/216	5/216	15/216	1/216	21/216	NR	20/216	215/216	10/216	104/216	51/216	NR	169/216	15/216	23/21
18/45	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
14/27	NR	5/27	13/27	NR	NR	NR	14/27	NR	NR	7/27	NR	NR	NR	NR
2/11	7/8	NR	NR	NR	6/8	NR	8/11	NR	NR	NR	1/11	NR	NR	NR
10/21	NR	NR	20/21	NR	NR	NR	21/21	NR	NR	NR	NR	NR	NR	NR
30/54	NR	16/54	31/54	NR	NR	NR	6/54	NR	NR	z	36/54	6/54	NR	NR
2/2	NR	NR	2/2	NR	1/2	NR	2/2	NR	NR	NR	NR	NR	NR	NR
2/4	NR	1/4	2/4	NR	2/4	NR	4/4	NR	NR	NR	NR	NR	NR	NR
NR	NR	NR	1/1	NR	NR	NR	1/1	NR	NR	NR	NR	NR	NR	NR
1/1	NR	1/1	1/1	1/1	NR	NR	1/1	NR	NR	NR	NR	NR	NR	NR
1/1	NR	1/1	1/1	NR	NR	NR	1/1	NR	NR	NR	NR	NR	NR	NR
1/1	NR		1/1	NR	NR	NR	1/1	NR	NR	NR	NR	NR	NR	NR
5/7	NR	NR	NR	NR	1/7	1/7	L/ L	NR	NR	NR	NR	2/7	NR	NR

IQR, interquartile range; SD, standard deviation; NR, not reported

Benites-Zapata et al. Ann Clin Microbiol Antimicrob (2022) 21:36

Page 5 of 18

or confirmed cases affected by the clinical characteristics or complications. We used the Web-based tool "Web-PlotDigitizer" to extract data from graphs in case it was not available in numerical format [25].

Risk of bias assessment

We used the original Newcastle-Ottawa Scale (NOS) to assess the risk of bias in case-control and cohort studies, and the NOS was adapted for cross-sectional studies (NOS-CS). In both scales, a score of 7 or more stars was considered a low risk of bias, while a score of 6 or fewer stars was considered a high risk of bias. The quality assessment of case reports and case series were assessed with the Joanna Briggs Institute's Checklist for Case Reports and Checklist for Case Series, respectively. As with the NOS and the NOS-C, the cut-off points for both checklists were seven stars. We assigned a star to every item answered as "Yes"; otherwise, it did not receive a star. In case multiple items were "Not applicable" for an article, the quality of the study was finally decided by consensus on a case-by-case basis. This examination was done independently by two reviewers (JRU-B and EAA-B).

Assessment of publication bias

The publication bias assessment in proportional metaanalysis is an evaluation that is not recommended in the current literature. That is because conventional funnel plots and Egger's test are inaccurate for these analyses. The reason behind this is that funnel plots were created assuming that studies with positive results were published more frequently when compared to studies with negative results; however, in a meta-analysis of proportions, there is no consensus on what a positive result is. Moreover, there is no evidence that proportions adjust correctly to funnel plots or Egger's tests [26, 27].

Statistical approach

The information collected from the included articles was combined using STATA 16.0. We conducted a pooled analysis of the various clinical manifestations, characteristics of the lesions and complications of patients with probable/confirmed monkeypox. A random-effects model (Dersimonian and Laird) was used for the quantitative analysis. The 95% Confidence Intervals for the proportions reported in each study were calculated using the Clopper-Pearson Method. The Freeman-Tukey Double Arcsine Transformation was used as the variance stabiliser. The Cochran's Q test and the I² statistic were used to assess the between-study-heterogeneity; values equal to or greater than 60% were classified as high heterogeneity for the I^2 statistic, and a P-value < 0.05 was a sign of heterogeneity in the Cochran's Q test. In addition, we carried out a subgroup analysis according to the continent where the studies were conducted (when there were at least two studies to meta-analyse) and a sensitivity analysis excluding studies classified as having a high risk of bias.

Results

Study selection and characteristics

The systematic search retrieved 4909 references across all databases, and duplicates were removed. Titles and abstracts screened the remaining 1285 references, and 59 articles remained for selection by full-text. After screening, 12 were included for quantitative synthesis (meta-analyses), and 19 studies were included in the qualitative synthesis [28-46]. The main characteristics of all included studies are summarised in Tables 1 and 2, and the study selection process is briefly described in the PRISMA flow diagram (Fig. 1).

Our review included nine cross-sectional studies, three cohort studies, four case reports, and three case series. Most of them were conducted in African countries (9 studies); the most extensive study was from Whitehouse et al. [31], and the smallest was from Learned et al. [37]. Case reports and case series were included only for qualitative synthesis and were the studies with the smallest populations. A total of 1958 patients from the remaining study designs were pooled in the quantitative synthesis. Males accounted for 57.6% (1129), and the age ranged from 2 days old to 69 years old. Most cross-sectional studies were at low risk of bias, and just two were at high risk. Likewise, all cohort studies, case series and case reports were at low risk of bias (Additional file 1: Table S3).

Monkeypox clinical findings

Regarding the clinical manifestations, rash (93%, 95% CI: 80-100%), fever (72%, 95% CI: 30-99%), pruritus (65%, 95% CI: 47-81%), and lymphadenopathy (62%, 95% CI:47-76%), were among the most prevalent clinical manifestations (Fig. 2). Other manifestations included fatigue (60%, 95% CI: 32-85%), sore throat (57%, 95% CI: 36-77%), headache (50%, 95% CI: 25-75%), cough (47%, 95% CI: 38-57%), myalgias (45%, 95% CI: 16-76%), photophobia (32%, 95% CI: 3-71%), arthralgia (26%, 95% CI: 1-65%), difficult breathing (25%, 95% CI: 3-58%), conjunctivitis (19%, 95% CI: 9-32%), nausea/vomiting (19%, 95% CI: 9-30%), diarrhea (4%, 95% CI: 2-7%) (Fig. 2).

Cutaneous lesions characteristics of monkeypox

The cutaneous lesions were mostly monomorphic (79%, 95% CI: 68-88%), instead of pleomorphic (38%, 95% CI: 12-68%), with a centrifugal distribution (81%, 95% CI: 59–96%), rather than centripetal (3%, 95% CI: 2–4%) (Fig. 3). About the number of lesions, in 50% (95% CI: 36-64%), there were < 100 lesions, and 50% (95% CI: 36-64%) had \geq 100 lesions. Regarding the lesion distribution, these were located at head/neck (74%, 95% CI: 49-92%), hand palms (80%, 95% CI: 53-97%), foot soles (72%, 95% CI: 58-84%), arms/hands (71%, 95% CI: 38-95%), chest/abdomen (69%, 95% CI: 28-97%), legs/ feet (61%, 95% CI: 36-83%), pelvic area and groins (45%, 95% CI: 16-76%), oral cavity (39%, 95% CI: 21-59%), mucosae of genitals (34%, 95% CI: 25-44%), and at the entire body (35%, 95% CI: 20-50%) (Fig. 3).

Complications, hospitalizations and deaths associated with monkeypox

Among the patients, 9% (95% CI 2–18%) presented ocular lesions, 18% (8–30%) secondary bacterial skin infections, 1% (0–7%) haemorrhagic pustules, and 10% (0–28%) ulcerated or necrotic lesions (Fig. 4). From the patients, 35% (14–59%) were hospitalized, and 4% (1–9%) had fatal outcomes (Fig. 4).

Subgroup analysis

In the subgroup analysis, fever, myalgias and lymphadenopathy occurred similarly between African and European patients (Additional file 1: Table S4). When comparing the frequency of rash, this was significantly higher in African studies (100%, 95% CI: 100-100%) than in European (22%, 95% CI: 14–32%) (Additional file 1: Table S1). At the same time, the distribution of the rash in the pelvic area and groins was significantly higher in European studies (75%, 95% CI: 65-84%) compared to the African (30%, 95% CI: 28-33%) (Additional file 1: Table S3). In addition, lymphadenopathy was slightly more frequent in Africa (65%, 95% CI: 47%-81%) than in Europe (54%, 95% CI: 43–65%). African patients were significantly more hospitalised (64%, 33-90%) than European (10%, 4–17%). Although no deaths have been reported in Europeans so far, all the deaths corresponded to African patients.

Sensitivity analysis

Regarding to the sensitivity analysis (Additional file 1: Table S5), the most common clinical findings were rash (93%, 95% CI: 80–100%), cough (47%, 95% CI: 38–57%), headache (55%, 95% CI: 29–81%), fatigue (75%, 95% CI: 55–90%), throat sore (57%, 95% CI:36–77%), lymphadenopathy (67%, 95% CI: 51–81%), and pruritus (55%, 95% CI: 52–58%).Monkeypox lesions were mainly monomorphic (79%, 95% CI: 68–88%) with a centrifugal body distribution (81%, 95% CI: 59–96%), and with more than 100 lesions (52%, 95% CI: 37–66%). The most common sites of rash were head and/or neck (74%, 95% CI: 49–72%),

arms and/or hands (71%, 95% CI: 38–95%), and palms (80%, 95% CI: 53–97%). The most prevalent complications were secondary bacterial skin infection (18%, 95% CI: 8–30%), hospitalization (18%, 95% CI: 8–30%), and ulcerated or necrotic lesions (10%, 95% CI: 0–28%).

Discussion

Over the last months, more than 18,000 cases of monkeypox have been reported outside Africa, in more than 70 countries (up to July 27, 2022), for the first time in more than five decades since the virus was first detected in humans [47–50]. Monkeypox is an emerging condition outside endemic countries, rapidly spreading to multiple countries and continents due to different factors, including its potential sexual transmission [51, 52]. Preparedness at different levels, facing a new clinical disease, demands efforts in epidemiological, diagnostic, therapeutic, and preventive fields during a potential pandemic [53] threatening to spread to new territories and areas with the risk of epidemics [41, 54–59].

Clinical findings and the evolution of the disease and outcomes constitute critical knowledge that should be carefully studied when a new infectious disease emerges or reemerge. Recently, in this context of the monkeypox outbreak, several questions have been raised, including what the full spectrum of illness is, which proportion of patients present complications, need hospitalisation, and may evolve to fatal forms [60-62]. In this systematic review and meta-analysis, we tried to initially summarise clinical data on monkeypox cases published during the outbreak's first weeks. As a result, we analysed more than 1900 patients for major clinical manifestations (most of them men). Our findings are consistent with the expected.

Initial observations from imported cases [46, 63–66], confirmed by this systematic review, suggest that monkeypox's clinical presentation and evolution would differ from the findings of African studies before 2022 and the publications in non-endemic European countries. This review confirms that rash with pruritus, fever, and lymphadenopathy are critical clinical findings, but now, in connection with the potential sexual transmission or transmission due to close contact during sex, is associated more in the 2022 outbreak with rash in the pelvic area and groins (75%) compared to its frequency in African patients (30%). The rash also seems to be different between the clinical presentation in Africa and Europe, with higher frequency in endemic countries (100%), whilst relatively low in European patients (22%). In some cases, yet to be confirmed in case series and more extensive studies, patients may present with solitary or few lesions [43]. Nevertheless, it is to note that 50% of the

\times
<u> </u>
\geq
-
÷
~
a
at
. <u> </u>
S
as
Ś
5
Ę
g
÷
8
5
Ŭ
Q
a
as
2
ę
Ŧ
0
S
÷
·=
Ę
g
aĽ.
Ë,
U
2
e
ą
Ъ

Author	Rash (affected _k	oatients/total pa	atients)		Lesions on	Number	Complicatio	ns (affected pa	itients/total pati	ents)		
	Monomorphic	Pleomorphic	Rash site	Body Distribution	mucous membranes (affected patients/ total patients)	of lesions (affected patients/ total patients)	Ocular lesions	Secondary bacterial skin infection	Hemorrhagic pustules	Ulcerated or necrotic lesions	Deaths	Hospitalised patients
Formenty et.al.	ž	٣	Entire Body: 8/11 Head and/ or neck: 3/8 Arms and/or hands: 3/8 Legs and/or feets: 3/8 Chest and/or Abdomen:	Ĕ	Oral cavity: 6/8	< 100: 3/6 > 100:3/6	Ж	٣	а Х	٣	0/19	61/2
Huhn et.al.	21/31	9/31	Entire Body: 7/31 Head or neck: 20/32 Arms or hands: 26/32 Pelvic area and groin: 3/32 Legs or feet: 21/32 Chest or Abdo- men:18/32	Centrifugal: 15/31 Centrip- etal:1/31	0ral cavity: 7/34	< 100: 24/30>100: 6/30	Ř	19/40	2/34	8/34	0/34	9/34
Yinka-Ogunl- eye et al.	25/40	15/40	Head and/or neck: 68/71 Arms and/or hands: 55/70 pelvic area and groin: 44/65 Legs and/or feets: 63/69 Chest and/or Abdomen:56/70 Palms: 48/70 Sole of the foot: 42/66	Ř	Genitals: 25/40	<100: 16/40>100: 24/40	Ж	19/40	щ	X	7/122	ж

Table 2 (coi	ntinued)											
Author	Rash (affected _k	oatients/total pé	atients)		Lesions on	Number	Complicatio	ins (affected pa	ntients/total pati	ents)		
	Monomorphic	Pleomorphic	Rash site	Body Distribution	mucous membranes (affected patients/ total patients)	or lesions (affected patients/ total patients)	Ocular lesions	Secondary bacterial skin infection	Hemorrhagic pustules	Ulcerated or necrotic lesions	Deaths	Hospitalised patients
Whitehouse et al.	286/319	۲ ۲	Head and/or neck:1036/1057 Arms and/ or hands: 1026/1057 Pelvic area and groin: 300/1057 Legs and/or feets: 786/1057 Chest and/ or heato- men:1028/1057 Palms: 1009/1057 v: 885/1057	Centrifugal: 989/1025 Centripetal: 33/1025	Oral cavity 570/1018 Genitals: 300/1057	<100: 510/1043 >100: 533/1043	٣	۲	X ک	۲ ۲	٣	۲ ۲
Ježek et al.	233/295	62/295	Head and/or neck: 256/295 Palms: 206/295 Sole of the foot: 196/295	Centrifugal: 245/295 Centripetal: 13/295	Oral cavity: 207/295 Genitals: 88/295 Conjunctiva: 57/295	< 100: 77 /295 > 100: 218/295	11/295	48/295	0/295	R	33/338	X
Kalthan et.al	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	3/12	10/12
Pittman et al.	NR	NR	NR	NR	Oral cavity: 53/216	NR	NR	18/216	6/216	NR	3/216	NR
Breman et.al.	NR	NR	NR	RN	NR	< 100: 24/47 > 100: 23/47	1/47	R	NR	R	8/47	NR
Perez-Duque	NR	NR	Pelvic area and groin: 6/27	NR	Genitals: 6/27	NR	NR	NR	NR	11/27	0/27	3/27
Learned et.al.	NR	NR	NR	NR	NR	<100: 6/8 > 100:2/8	1/11	NR	NR	NR	0/11	8/11
Mande et al.	18/21	3/21	Arms and/or hands: 18/21 Sole of the foot:15/21	NR	NR	NR	8/21	NR	Z	NR	ХХ	NR

Table 2 (coi	ntinued)											
Author	Rash (affected _k	oatients/total pa	atients)		Lesions on	Number	Complicatio	ns (affected pa	itients/total pati	ents)		
	Monomorphic	Pleomorphic	Rash site	Body Distribution	mucous membranes (affected patients/ total patients)	or resions (affected patients/ total patients)	Ocular lesions	Secondary bacterial skin infection	Hemorrhagic pustules	Ulcerated or necrotic lesions	Deaths	Hospitalised patients
Girometti etal.	٣	48/54	Head or neck: 11/54 Arms or hands: 11/54 Pelvic area and groin: 51/54 Legs or feet: 11/54 Chest or Abdomen: 14/54	٣	Oral cav- ity:4/54	۳	٣	6/54	۳	ж Z	Ж	5/54
Vaughan et al.	NR	NR	Pelvic area and groin: 1/2	NR	Oral cavity: 1/2	NR	NR	NR	NR	NR	NR	NR
Antinori et al.	٣	ж	Head or neck: 1/4 Pelvic area and groin: 3/4 Legs or feet: 3/4 Cles or Abdo- men: 2/4 Sole of the foot:1/4	ĸ	Anal or rectal area: 2/4	ж	ж	ж	٣	х	XX	ж Х
Hammer- schlag et al.	Я	NR	Pelvic area and groin: 1/1 Head or neck: 1/1 Chest or Abdo- men: 1/1	Ж	R	NR	NR	NR	X	X	Х	X
De Nicolas- Ruanes et al.	NR	NR	Pelvic area and groin: 1/1	NR	Anal or rectal area: 1/1	NR	NR	NR	NR	1/1	NR	NR
Erez et al.	NR	NR	Entire Body: 1/1	NR	NR	NR	NR	NR	NR	1/1	NR	NR

<u> </u>
÷
0
Ō
9
2
Ð
-
0
ъ.
-

Table 2 (C	ontinued)											
Author	Rash (affected	patients/total p	atients)		Lesions on	Number	Complicatio	ns (affected pa	tients/total pati	ents)		
	Monomorphic	Pleomorphic	Rash site	Body Distribution	mucous membranes (affected patients/ total patients)	of lesions (affected patients/ total patients)	Ocular lesions	Secondary bacterial skin infection	Hemorrhagic pustules	Ulcerated or necrotic lesions	Deaths	Hospitalised patients
Adler et al.	登	7/7	Head or neck://7 Arms or hands: 3/7 pelvic area and groin:4/7 Legs or feet: 1/7 Chest or Abdo- men:7/7 Sole of the foot:2/7	X	X	ж Z	N	0/2	X	2/7	0/7	7/7
<u>NR</u> not report	ed											

Benites-Zapata et al. Ann Clin Microbiol Antimicrob (2022) 21:36

epc



patients show 100 or more cutaneous lesions, which corresponds to the severe skin lesion severity score of the World Health Organization [67].

Even more, and fortunately, the disease is milder in the current outbreak and outside Africa, with a rate of hospitalisation approximately of 1:6 between Europeans versus African patients, with no deaths reported so far in the ongoing outbreak outside endemic countries. This pattern is probably associated with the circulation of the milder West African clade. A recent systematic review exclusively assessing the case fatality rates (CFR%) by clades found that the CFR% for the West African clade (3.6%, 95% CI 1.7–6.8%) was significantly lower than the Central African clade (10.6%, 8.4–13.3%) [68]. Given the higher frequency of rash (93%) but also of fever (72%), the differential diagnoses of monkeypox will be broad and also dependent on the local epidemiology, including multiple vaccine-preventable diseases such measles, varicella, or even arboviral diseases in the tropics (e.g. dengue, chikungunya, Zika) [69], as well as other established sexually transmitted infections, such as syphilis and AIDS dermatitis, but also the increasing report of this zoonotic infection among people living with HIV/AIDS [18, 36, 41, 42, 70–74]. Moreover, cutaneous lesions or rash appear, as confirmed in this systematic review, head/neck, hand palms and foot soles (>70%)

Author	n	Ν		ES (95% CI)	Author	n	Ν		ES (95% CI)
					Lymphadenopathy				
ever					Breman JG et.al	18	45		0.40 (0.26, 0.56
ormenty P et.al	16	19	-	0.84 (0.60, 0.97)	Formenty P et.al	15	19		- U.79 (0.54, 0.94
Girometti N et.al	31	54		- 0.57 (0.43, 0.71)	Girometti N et.al	30	54		0.56 (0.41, 0.69
Juhn G et al	28	34		0.82 (0.65, 0.93)	Huhn G et.al	19	34		0.56 (0.38, 0.73
	20	40		- 0.02 (0.00, 0.03)	Ježek Z et.al	163	295	-	0.55 (0.49, 0.6
aitnan E et.al	11	12	-	■ 0.92 (0.62, 1.00)	Kalthan E et.al	6	12	-	0.50 (0.21, 0.79
∕lande G et.al	20	21		0.95 (0.76, 1.00)	Learned L et.al	2	11	-	0.18 (0.02, 0.5)
	13	27		- 0.48 (0.29, 0.68)	Mande G et.al	10	21	_	0.48 (0.26, 0.7)
elez-Duque M	13	21	-	- 0.48 (0.29, 0.00)	Perez-Duque M	14	27		0 52 (0 32 0 7
Pittman P et.al	1	216	•	0.00 (0.00, 0.03)	Pittman P et al	213	216		0.99 (0.96, 1.00)
Whitehouse E. et.al	1023	1057	•	 0.97 (0.96, 0.98) 	Whitebouse E et al	876	103/		 0.85 (0.82, 0.83)
/inka-Ogunlovo A ot al	81	92			Viniteriouse E. et al	45	65		0.00 (0.02, 0.01)
	01	52		= 0.00 (0.00, 0.04)	Cubtatal (IA2 - 06 200)	40	05	-	0.09 (0.57, 0.80
Subtotal $(1^2 = 99.37\%)$, p = 0.0	JU)		0.72 (0.30, 0.99)	Subiolar (1-2 = 90.36%, p	- 0.00)		\sim	0.02 (0.47, 0.76
Arthralaia					Photophobia				
	45	40		- 0.70 (0.54, 0.04)	Learned L et.al	7	8		0.88 (0.47, 1.00)
ormenty P et.al	15	19	_	0.79 (0.54, 0.94)	Pittman P et.al	5	216	•	0.02 (0.01, 0.05
luhn G et.al	2	34	-	0.06 (0.01, 0.20)	Whitehouse E. et.al	332	999	•	0.33 (0.30, 0.3
Pittman P et al	21	216	+	0 10 (0 06 0 14)	Subtotal (I ² = .%, p = .)				0.32 (0.03, 0.7
	~ '	210		0.10 (0.00, 0.14)					
Subtotal (I^2 = .%, p = .	.)		\sim	0.26 (0.01, 0.65)	Myalgias				
					Formenty P et al	15	10		0.79/0.54.0.0
Pruritus					Girometti N ot al	16	54		0.10 (0.04, 0.94
Tuntus	~	~				10	04		0.50 (0.16, 0.44
earned L et.al	6	8		—— 0.75 (0.35, 0.97)	Hunn G et.al	19	34		0.56 (0.38, 0.73
Whitehouse E. et.al	542	1012	-	0.54 (0.50, 0.57)	Perez-Duque M	5	27		0.19 (0.06, 0.38
(inka-Ogunleve A et al	57	78	-	0 73 (0 62 0 82)	Pittman P et.al	15	216	.	0.07 (0.04, 0.11
	, ⁰	, 0			Whitehouse E. et.al	754	1003	•	0.75 (0.72, 0.78
$(1^{2} = .\%, p = .)$.)		<	0.65 (0.47, 0.81)	Yinka-Ogunleye A et.al	42	67		0.63 (0.50, 0.74
					Subtotal (I^2 = 98.75%, p	= 0.00)		\sim	0.45 (0.16, 0.7
			0 .2 .4 .6	.8 1				0 .2 .4 .6 .8	3 1
uthor	n	N		ES (95% CI)	Author	n	N		ES (95% CI)
Conjunctivitis		40	-	0.50 (0.22, 0.00)	Headache Formenty R et al	11	19		0.58 (0.33, 0.80)
ormenty P et.al	11	19		0.58 (0.33, 0.80)	Hube C et al	22	24		0.55 (0.55, 0.60)
luhn G et.al	3	34	-	0.09 (0.02, 0.24)	Hunn G et.al	22	34		0.65 (0.46, 0.80)
'ittman P et.al	20	216	+	0.09 (0.06, 0.14)	Kaithan E et.al	2	12		0.17 (0.02, 0.48)
		1016		0.21 (0.18, 0.23)	Perez-Duque M	7	27		0.26 (0.11, 0.46)
Vhitehouse F et al	210		-	0.21 (0.10, 0.20)	Pittman P et.al	51	240		0 24 (0 18 0 30)
Whitehouse E. et.al	210						210	-	0.24 (0.10, 0.00)
Vhitehouse E. et.al subtotal (I^2 = 91.14%, p = 0.00)	210		\sim	0.19 (0.09, 0.32)	Whitehouse E. et.al	793	1011	-	0.78 (0.76, 0.81)
Vhitehouse E. et.al subtotal (I^2 = 91.14%, p = 0.00)	210		\sim	0.19 (0.09, 0.32)	Whitehouse E. et.al Yinka-Ogunleye A et.al	793 61	1011 77	-	0.78 (0.76, 0.81) 0.79 (0.68, 0.88)
Vhitehouse E. et.al subtotal (I^2 = 91.14%, p = 0.00) Rash	210		\sim	0.19 (0.09, 0.32)	Whitehouse E. et.al Yinka-Ogunleye A et.al Subtotal (I^2 = 97.85%, p = 0.00)	793 61	1011 77	<u> </u>	0.78 (0.76, 0.81) - 0.79 (0.68, 0.88) 0.50 (0.25, 0.75)
Vhitehouse E. et.al subtotal (I^2 = 91.14%, p = 0.00) tash formenty P et.al	210	19	\checkmark	0.19 (0.09, 0.32) ■ 1.00 (0.82, 1.00)	Whitehouse E. et.al Yinka-Ogunleye A et.al Subtotal (I^2 = 97.85%, p = 0.00)	793 61	210 1011 77		0.78 (0.76, 0.81) - 0.79 (0.68, 0.88) 0.50 (0.25, 0.75)
Vhitehouse E. et.al iubtotal (I^2 = 91.14%, p = 0.00) tash formenty P et.al Girometti N et.al	210 19 6	19 54	 ✓ 	0.19 (0.09, 0.32) ■ 1.00 (0.82, 1.00) 0.11 (0.04, 0.23)	Whitehouse E. et.al Yinka-Ogunleye A et.al Subtotal (I*2 = 97.85%, p = 0.00) Fatioue	793 61	210 1011 77	\sim	- 0.79 (0.68, 0.88) 0.50 (0.25, 0.75)
Vhitehouse E. et.al kubtotal (I^2 = 91.14%, p = 0.00) tash formenty P et.al kirometti N et.al luhn G et.al	210 19 6 32	19 54 34	 ✓ 	0.19 (0.09, 0.32) ■ 1.00 (0.82, 1.00) 0.11 (0.04, 0.23) 	Whitehouse E. et.al Yinka-Ogunleye A et.al Subtotal (1^2 = 97.85%, p = 0.00) Faligue Formenty P et.al	793 61 12	210 1011 77 19	<u> </u>	0.78 (0.76, 0.81) - 0.79 (0.68, 0.83) 0.50 (0.25, 0.75)
Vhitehouse E. et.al vubtotal (I^2 = 91.14%, p = 0.00) Rash iormenty P et.al iormetti N et.al tubn G et.al case Z et al	210 19 6 32 295	19 54 34	 ► 	0.19 (0.09, 0.32) →■ 1.00 (0.82, 1.00) 0.11 (0.04, 0.23) →■ 0.94 (0.80, 0.99) ■ 1.00 (0.99, 4.00)	Whitehouse E, et al Yinka-Ogunleye A et al Subtotal (I ^A 2 = 97.85%, p = 0.00) Faligue Formenty P et al Girometh N et al	793 61 12 36	210 1011 77 19 54		0.78 (0.76, 0.81) - 0.79 (0.82, 0.81) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.72)
Vhitehouse E. et.al Jubtotal (I^2 = 91.14%, p = 0.00) tash ormently P et.al Jirometti N et.al Jubn G et.al ežek Z et.al	210 19 6 32 295	19 54 34 295	 ► 	0.19 (0.09, 0.32) → 1.00 (0.82, 1.00) 0.11 (0.04, 0.23) → 0.94 (0.80, 0.99) 1.00 (0.99, 1.00) 4.00 (0.71, 1.00)	Vinitehouse E. et al Yinka-Ogunleye A et al Subtotal (IP2 e 91.85%, p = 0.00) Fatigue Formenty P et al Giorometti N et al La samed i et al	793 61 12 36	210 1011 77 19 54 11		0.78 (0.76, 0.81) - 0.79 (0.68, 0.83) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.79) 0.09 (0.62, 0.41)
Vhitehouse E. et.al vubtotal (I/2 = 91.14%, p = 0.00) tash öromenty P et.al örometti N et.al tuhn G et.al ezek Z et.al ialthan E. et.al	210 19 6 32 295 12	19 54 34 295 12	+	0.19 (0.09, 0.32) → ■ 1.00 (0.82, 1.00) 0.11 (0.04, 0.23) → ■ 0.94 (0.80, 0.99) ■ 1.00 (0.99, 1.00) ■ 1.00 (0.74, 1.00)	Whitehouse E, et al Yinka-Qounley A et al Subtotal (I*2 = 97.85%, p = 0.00) Fatgue Formenty P et al Giornetti N et al Learned L et al	793 61 12 36 1	210 1011 77 19 54 11		0.78 (0.76, 0.81) - 0.79 (0.68, 0.83) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.79) 0.09 (0.00, 0.41) 0.95 0.92
Vhitehouse E. et al Jubiotal (#2 = 91.14%, p = 0.00) tash Gromenty P et al Jionometti N et al Jubin G et al dathan E et al earned L et al	210 19 6 32 295 12 8	19 54 34 295 12 11	• 	0.19 (0.09, 0.32) 	Whitehouse E, et al Yinka-Ogunkye A et al Subtoal (J = 97.85%, p = 0.00) Falique Formenty P et al Giorneth H et al Learned L et al Whitehouse E, et al	793 61 12 36 1 888	210 1011 77 19 54 11 1029		0.78 (0.76, 0.81) - 0.79 (0.68, 0.83) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.79) 0.09 (0.00, 0.41) • 0.86 (0.84, 0.82) • 0.80 (0.34, 0.88)
Vhitehouse E. et al uubtotal (P/2 = 91.14%, p = 0.00) kash örometti P et al örometti N et al uuhn G et al earned L et al hande G et al	210 19 6 32 295 12 8 21	19 54 34 295 12 11 21	• 	0.19 (0.09, 0.32) → 1.00 (0.82, 1.00) 0.11 (0.04, 0.23) → 0.94 (0.80, 0.99) 1.00 (0.99, 1.00) → 1.00 (0.74, 1.00) → 0.73 (0.39, 0.94) → 0.73 (0.39, 0.94) → 0.00 (8.4, 1.00)	Whitehouse E, et al Yrins-Ogunkeye A et al Subtotal (I*2 = 97.85%, p = 0.00) Fatigue Formenty P et al Giornell N et al Learned L et al Whitehouse E et al Subtotal (I*2 = 93.71%, p = 0.00)	793 61 12 36 1 888	1011 77 19 54 11 1029		0.78 (0.76, 0.81) - 0.79 (0.68, 0.88) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.79) 0.09 (0.00, 0.41) 0.86 (0.84, 0.88) - 0.660 (0.32, 0.85)
Whitehouse E. et al uubtotal (h² = 91.14%, p = 0.00) tash ormenty P et al ormenty N et al uhun G et al ežek 2 et al talthan E et al earned L et al tande G et al terez-Duque M	210 19 6 32 295 12 8 21 14	19 54 34 295 12 11 21 27	+ 	0.19 (0.09, 0.32) → 1.00 (0.82, 1.00) 0.11 (0.04, 0.23) → 0.94 (0.80, 0.99) ■ 1.00 (0.99, 1.00) ■ 0.073 (0.39, 0.94) → 1.00 (0.84, 1.00) → 0.52 (0.32, 0.71)	Whitehouse E, et al Yints-Ogunitye A et al Subtiad ($t^{12} = 97.85\%$, $p = 0.00$) Fatigue Formenty P et al Girometti N et al Learned L et al Whitehouse E, et al Subtial ($t^{12} = 93.71\%$, $p = 0.00$)	793 61 12 36 1 888	1011 77 19 54 11 1029		0.78 (0.76, 0.81) 0.78 (0.76, 0.81) 0.59 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.79) 0.99 (0.00, 0.41) 0.86 (0.84, 0.83) 0.60 (0.32, 0.85)
Vhitehouse E. et al uubtotal (h/2 = 91.14%, p = 0.00) kash ormenty P et al ormenty P et al uhn G et al ezek Z et al althan E et al earned L et al fande G et al errez-Duque M Kitman P et al	210 19 6 32 295 12 8 21 14 215	19 54 34 295 12 11 21 27 216	+ 	0.19 (0.09, 0.32) → 1.00 (0.82, 1.00) 0.11 (0.04, 0.23) → 0.94 (0.80, 0.99) 1.00 (0.79, 1.00) → 1.00 (0.74, 1.00) → 0.73 (0.39, 0.94) → 1.00 (0.84, 1.00) → 0.52 (0.32, 0.71) 1.00 (0.97, 1.00)	Whitehouse E, et al Yrins-Oguneye A, et al Subtotal (I*2 = 97.85%, p = 0.00) Fatigue Formenty P et al Gioromti N et al Learned L et al Whitehouse E, et al Subtotal (I*2 = 93.71%, p = 0.00) Sore Throat	793 61 12 36 1 888	1011 77 19 54 11 1029		0.78 (0.76, 0.81) 0.78 (0.76, 0.81) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.79) 0.99 (0.00, 0.41) 0.86 (0.84, 0.85) 0.660 (0.32, 0.85)
hhiehouse E. et al uubotal (h² = 91.14%, p = 0.00) tash ormenty P et al ormenty P et al ormenty P et al ezek 2 et al talhan E et al earned L et al tande G et al rerez-Duque M titman P et al bitchehure E et al	210 19 6 32 295 12 8 21 14 215 1057	19 54 34 295 12 11 21 27 216 1057	+ 	0.19 (0.09, 0.32) → 1.00 (0.82, 1.00) 0.11 (0.04, 0.23) → 0.94 (0.80, 0.99) = 1.00 (0.74, 1.00) → 0.73 (0.39, 0.94) → 1.00 (0.84, 1.00) → 0.52 (0.32, 0.71) = 1.00 (0.97, 1.00) = 1.00 (0.97, 1.00)	Whitehouse E, et al Yink-Ogunkeç A et al Subtotal (Ir'2 = 97.85%, p = 0.00) Fatigue Formenty P et al Girometti N et al Learned L et al Whitehouse E, et al Subtotal (Ir'2 = 93.71%, p = 0.00) Store Throat Girometti N et al	793 61 12 36 1 888	210 1011 77 19 54 11 1029 54		
Vhitehouse E. et al uubtotal (h/2 = 91.14%, p = 0.00) kash ormenty P et al ormenty P et al uhn G et al each Z et al fande G et al fande G et al fande G et al Vhitehouse E. et al C = 0.000 = 0.0000 Vhitehouse E. et al	210 19 6 32 295 12 8 21 14 215 1057 1027	19 54 34 295 12 11 21 27 216 1057	+ 	0.19 (0.09, 0.32) → 1.00 (0.82, 1.00) 0.11 (0.04, 0.23) → 0.94 (0.80, 0.99) 1.00 (0.79, 1.00) → 1.00 (0.74, 1.00) → 0.73 (0.39, 0.94) → 1.00 (0.84, 1.00) - 0.52 (0.32, 0.71) 1.00 (0.97, 1.00) → 1.00 (0.97, 1.00) → 1.00 (0.97, 1.00) → 0.92 (0.92, 0.92)	Whitehouse E, et al Yrins-Oguneye A, et al Subtotal (P'2 = 97.85%, p = 0.00) Fatigue Formenty P et al GioromEt N et al Learned L et al Whitehouse E, et al Subtotal (P'2 = 63.71%, p = 0.00) Sore Throat GioromEt N et al Hutho G et al	793 61 12 36 1 888 6 21	210 1011 77 19 54 11 1029 54 34		0.76 (0.76, 0.81) 0.76 (0.76, 0.81) 0.79 (0.88, 0.83) 0.50 (0.25, 0.75) 0.65 (0.33, 0.78) 0.67 (0.53, 0.79) 0.09 (0.00, 0.41) 0.56 (0.32, 0.85) 0.11 (0.04, 0.23) 0.52 (0.44, 0.78)
Nhitehouse E. et al uubtotal (h² = 91.14%, p = 0.00) tash ormenty P et al ormenty N et al uhun G et al ežek Z et al talthan E et al earned L et al earned L et al tarde G et al rez-Duque M Yittman P et al Nhitehouse E. et al înka-Ogunitye A et al	210 19 6 32 295 12 8 21 14 215 1057 122	19 54 34 295 12 11 21 21 21 216 1057 122	+ 	0.19 (0.09, 0.32) → 1.00 (0.82, 1.00) 0.11 (0.04, 0.23) → 0.94 (0.80, 0.99) → 1.00 (0.99, 1.00) → 0.73 (0.39, 0.94) → 1.00 (0.84, 1.00) → 0.52 (0.32, 0.71) → 1.00 (0.97, 1.00) → 1.00 (0.97, 1.00) → 1.00 (0.97, 1.00)	Whitehouse E, et al Yrins-Ogunkeye A et al Subtotal (Y'2 = 97.85%, p = 0.00) Fatigue Formenty P et al Girometh H et al Subtotal (Y'2 = 93.71%, p = 0.00) Sore Throat Girometh H et al Huhn G et al Pittman P et al	793 61 12 36 1 888 6 21 169	216 1011 77 19 54 11 1029 54 34 216		−
Vhitehouse E. et al uubtotal (h/2 = 91.14%, p = 0.00) kash ormenty P et al ormenty P et al uhn G et al dek 2 et al talthan E et al earned L et al fande G et al farez-Duque M titman P et al Vhitehouse E. et al Tinka-Ogunleye A et al ubtotal (h/2 = 97.32%, p = 0.00)	210 19 6 32 295 12 8 21 14 215 1057 122	19 54 34 295 12 11 21 27 216 1057 122	+ 	0.19 (0.09, 0.32) 	Whitehouse E, et al Yrins-Oguneye a, et al Subtotal (P'2 = 97.85%, p = 0.00) Fatigue Formenty P et al GioromEt N et al Learned L et al Whitehouse E, et al Subtotal (P'2 = 93.71%, p = 0.00) Sore Throat GioromEt N et al Huhro G et al Pittman P et al Whitehouse E, et al	793 61 12 36 1 888 6 21 169 246	210 1011 77 19 54 11 1029 54 34 216 325		0.75 (0.76, 0.81) 0.75 (0.76, 0.81) 0.75 (0.83, 0.83) 0.50 (0.25, 0.75) 0.50 (0.25, 0.75) 0.50 (0.25, 0.79) 0.50 (0.00, 0.41) 0.56 (0.43, 0.85) 0.11 (0.04, 0.23) 0.52 (0.44, 0.78) 0.75 (0.72, 0.84) 0.76 (0.72, 0.84)
$\label{eq:product} \begin{array}{l} \text{whitehouse E. et al } \\ \text{whotcal } (k^2 = 91.14\%, p = 0.00) \\ \text{kash} \\ \text{ormenty P et al } \\ \text{ormenty N et al } \\ \text{whot G et al } \\ \text{ežek 2 et al } \\ \text{kathan E et al } \\ \text{earned L et al } \\ \text{arede G et al } \\ \text{rerez-Duque M } \\ \text{Withehouse E. et al } \\ \text{inka-Qgunleye A et al } \\ \text{inka-Qgunleye A et al } \\ \text{whotehouse I } (k^2 = 97.32\%, p = 0.00) \\ \end{array}$	210 19 6 32 295 12 8 21 14 215 1057 122	19 54 34 295 12 11 21 27 216 1057 122	+ 	0.19 (0.09, 0.32) 	Whitehouse E, et al Yrins-Ogunkeye A, et al Subtotal (IY2 = 97.85%, p = 0.00) Fatgue Formenty P et al Girometti N et al Learned L et al Whitehouse E, et al Subtotal (IY2 = 93.71%, p = 0.00) Sore Throat Girometti N et al Huhan G et al Whitehouse E, et al Whitehouse E, et al	793 61 12 36 1 888 6 21 169 246 45	210 1011 77 19 54 11 1029 54 34 216 325 77		−
Vhitehouse E. et al uubtotal (h/2 = 91.14%, p = 0.00) kash ormenty P et al ormenty P et al uhn G et al ezek 2 et al athan E et al earned L et al timan P et al Vhitehouse E. et al Tinka-Ogunjeye A et al ubtotal (h/2 = 97.32%, p = 0.00) Jiarrhea	210 19 6 32 295 12 8 21 14 215 1057 122	19 54 34 295 12 11 21 21 21 21 216 1057 122	+ 	0.19 (0.09, 0.32) 	Whitehouse E, et al Yrins-Oguneye A, et al Subtotal (P'2 = 97.85%, p = 0.00) Faligue Formenty P et al GioromE IX et al Learned L et al Whitehouse E, et al Subtotal (P'2 = 93.71%, p = 0.00) Sore Throat GioromE IX et al Huth G et al Pittman P et al Whitehouse E, et al Yrins-Oguneye A, et al Subtotal (P'2 = et 20% e. 0.00)	793 61 12 36 1 888 6 21 169 246 45	216 1011 77 19 54 11 1029 54 34 216 325 77	+ + + + + + + + + + + + + + + + + + +	0.75 (0.76, 0.81) 0.75 (0.76, 0.81) 0.50 (0.25, 0.81) 0.50 (0.25, 0.55) 0.50 (0.25, 0.75) 0.50 (0.25, 0.79) 0.99 (0.00, 0.41) 0.95 (0.42, 0.85) 0.11 (0.04, 0.23) 0.62 (0.44, 0.75) 0.78 (0.72, 0.84) 0.76 (0.72, 0.84) 0.55 (0.47, 0.70) 0.57 (0.6 0, 77.
Whitehouse E. et al uubtotal (%2 = 91.14%, p = 0.00) tash ormenty P et al ormenty N et al uuhon G et al ezek Z et al talthan E et al earned L et al earned L et al transe G et al rerez-Duque M Yittman P et al Vikiehouse E. et al inka-Ogunieye A et al uubtotal (%2 = 97.32%, p = 0.00) Jiarrhea ormentv P et al	210 19 6 32 295 12 8 21 14 215 1057 122 2	19 54 34 295 12 11 21 21 27 216 1057 122	+ 	0.19 (0.09, 0.32) 	Whitehouse E, et al Yrins-Ogunkeş A et al Subtotal ($V^2 = 97.85\%$, $p = 0.00$) Fatgue Formenty P et al Giornetti N et al Learned L et al Vhitehouse E, et al Subtotal ($V^2 = 93.71\%$, $p = 0.00$) Sore Throat Giornetti N et al Huhn G et al Whitehouse E, et al Whitehouse E, et al Subtotal ($V^2 = 96.28\%$, $p = 0.00$)	793 61 12 36 1 888 6 21 169 246 45	216 1011 77 19 54 11 1029 54 34 216 325 77	+ + + + + + + + + + + + +	0.76 (0.76, 0.81) 0.76 (0.76, 0.81) 0.76 (0.76, 0.81) 0.76 (0.76, 0.81) 0.57 (0.53, 0.54) 0.57 (0.53, 0.54) 0.56 (0.32, 0.85) 0.56 (0.32, 0.85) 0.56 (0.32, 0.85) 0.51 (0.04, 0.23) 0.52 (0.44, 0.73) 0.57 (0.71, 0.80) 0.58 (0.77, 0.70) 0.57 (0.36, 0.77)
hhiehouse E. et al uubtotal (h2 = 91.14%, p = 0.00) tash ormenty P et al ormenty P et al who G et al adhan E et al earned L et al earned L et al earned L et al futtiman P et al hithehouse E. et al hithea-Qualeye A et al hithetouse E. et al hithe-Qualeye A et al hithetouse E. et al hithe-Qualeye A et al hithetouse P. et al hithetouse P. et al hithetouse P. et al	210 19 6 32 295 12 8 21 14 215 1057 122 2 2	19 54 34 295 12 11 21 27 216 1057 122	+ 	0.19 (0.09, 0.32) 	Whitehouse E, et al Yrins-Oguneye A, et al Subtotal (P'2 = 97.85%, p = 0.00) Faligue Formenty P et al GioromEl N et al Learned L et al Whitehouse E, et al Subtotal (P'2 = 93.71%, p = 0.00) Sore Throat GioromEl N et al Hufto G et al Ptitman P et al Yinka-Oguneye A, et al Subtotal (P'2 = 96.23%, p = 0.00)	793 61 12 36 1 888 6 21 169 246 45	210 1011 77 19 54 11 1029 54 34 216 325 77		0.75 (0.76, 0.81) 0.75 (0.76, 0.81) 0.79 (0.88, 0.83) 0.50 (0.25, 0.75) 0.50 (0.25, 0.75) 0.50 (0.25, 0.79) 0.09 (0.00, 0.41) 0.05 (0.44, 0.85) 0.11 (0.04, 0.23) 0.62 (0.44, 0.75) 0.78 (0.72, 0.84) 0.76 (0.71, 0.80) 0.55 (0.47, 0.70) 0.57 (0.36, 0.77)
Whitehouse E. et al uubtotal (%2 = 91.14%, p = 0.00) tash ormenty P et al ormenty N et al uuhon G et al ezek Z et al tante G et al erez-Duque M Witman P et al Whitehouse E. et al Tinka-Ogunleye A et al uubtotal (%2 = 97.32%, p = 0.00) Jiarrhea ormenty P et al Uuh G et al et al Second Seco	210 19 6 32 295 12 8 21 14 215 1057 122 2 2 2 2	19 54 34 295 12 11 21 27 216 1057 122 19 34	+ +	0.19 (0.09, 0.32) 	Whitehouse E, et al Yrins-Oguneye A, et al Subtotal (Y2 = 97.85%, p = 0.00) Fatgue Formenty P et al Giornetti N et al Learnet L et al Whitehouse E et al Subtotal (Y2 = 93.71%, p = 0.00) Sore Throat Giornetti N et al Hutin G et al Pittman P et al Whitehouse E, et al Subtotal (Y2 = 96.28%, p = 0.00) Difficulty Breathing Economic et al	793 61 12 36 1 888 6 21 169 246 45	210 1011 77 19 54 11 1029 54 34 216 325 77		 0.76 (0.76, 0.81) 0.79 (0.68, 0.83) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.73) 0.96 (0.00, 0.41) 0.86 (0.84, 0.83) 0.60 (0.32, 0.85) 0.11 (0.04, 0.23) 0.62 (0.44, 0.73) 0.52 (0.44, 0.73) 0.53 (0.37, 0.71) 0.58 (0.74, 0.70) 0.57 (0.36, 0.77) 0.57 (0.36, 0.77)
hhiehouse E. et al uubtotal (h² = 91.14%, p = 0.00) kash ormenty P et al ormenty P et al ormenty N et al uuhn G et al ezek Z et al athan E et al earned L et al earned L et al triman P et al Whiehouse E. et al hick-Ogunipe A et al ubtotal (h² = 97.32%, p = 0.00) biarrhea ormenty P et al luhn G et al Timan P et al	210 19 6 32 295 12 8 21 14 215 1057 122 2 10	19 54 34 295 12 11 21 27 216 1057 122 19 34 216	+ 	0.19 (0.09, 0.32) 100 (0.82, 1.00) 0.11 (0.04, 0.23) 0.94 (0.80, 0.99) 100 (0.99, 1.00) 100 (0.74, 1.00) 0.73 (0.39, 0.94) 100 (0.84, 1.00) 0.52 (0.32, 0.71) 100 (0.97, 1.00) 100 (1.00, 1.00) 0.93 (0.80, 1.00) 0.93 (0.80, 1.00) 0.93 (0.80, 1.00) 0.93 (0.80, 1.00) 0.93 (0.02, 0.08)	Whitehouse E, et al Yrins-Oguneye a, et al Subtotal (P'2 = 97.85%, p = 0.00) Faligue Formenty P et al Giornett H et al Learned L et al Whitehouse E, et al Subtotal (P'2 = 93.71%, p = 0.00) Sore Throat Giornett H et al Hutha G et al Pittnan P et al Yrins-Oguneye A et al Subtotal (P'2 = 96.28%, p = 0.00) Difficulty Breathing Formently P et al	793 61 12 36 1 888 6 21 169 246 45	210 1011 77 19 54 11 1029 54 34 216 325 77 19		0.75 (0.75 6.81) 0.75 (0.75 6.81) 0.75 (0.88, 0.83) 0.50 (0.25, 0.55) 0.50 (0.25, 0.57) 0.50 (0.25, 0.79) 0.50 (0.25, 0.79) 0.50 (0.32, 0.84) 0.57 (0.32, 0.79) 0.56 (0.32, 0.85) 0.11 (0.04, 0.23) 0.52 (0.44, 0.75) 0.76 (0.72, 0.84) 0.55 (0.47, 0.70) 0.55 (0.47, 0.70) 0.55 (0.47, 0.70) 0.55 (0.54, 0.77) 0.55 (0.54, 0.77)
hitehouse E. et al ubtotal (h ² C = 91.14%, p = 0.00) lash ormenty P et al ormenty P et al who G et al zek Z et al althan E et al bared L et al lande G et al erez-Duque M titman P et al hitehouse E. et al hitehouse A et al ubtotal (h ² C = 97.32%, p = 0.00) iarrhea somenty P et al uhn G et al titman P et al bototal (h ² C = %, p = .)	210 19 6 32 295 12 8 21 14 215 1057 122 2 2 10	19 54 34 295 12 11 21 21 21 21 216 1057 122	← 	0.19 (0.09, 0.32) 100 (0.82, 1.00) 0.11 (0.04, 0.23) 0.94 (0.80, 0.99) 100 (0.99, 1.00) 0.73 (0.39, 0.94) 100 (0.84, 1.00) 0.52 (0.32, 0.71) 1.00 (0.97, 1.00) 1.00 (0.97, 1.00) 0.93 (0.80, 1.00) 0.93 (0.80, 1.00) 0.11 (0.01, 0.33) 0.05 (0.01, 0.20) 0.05 (0.01, 0.20) 0.04 (0.02, 0.07)	Whitehouse E, et al Yrins-Ogunkye A et al Subtotal (I*2 = 97.85%, p = 0.00) Fatgue Formenty P et al Giornetti N et al Learnet L et al Yrihebouse E et al Subtotal (I*2 = 93.71%, p = 0.00) Sore Throat Giornetti N et al Huho G et al Yrins-Ogunkye A et al Subtotal (I*2 = 98.25%, p = 0.00) Difficulty Greathing Formenty P et al Huho G et al	793 61 12 36 1 888 6 21 169 246 45 12 6	210 1011 77 19 54 11 1029 54 34 216 325 77 19 34		 0.76 (0.76, 0.81) 0.77 (0.56, 0.81) 0.79 (0.56, 0.81) 0.50 (0.25, 0.75) 0.50 (0.25, 0.75) 0.50 (0.25, 0.75) 0.50 (0.25, 0.75) 0.50 (0.32, 0.84) 0.76 (0.71, 0.80) 0.56 (0.44, 0.75) 0.76 (0.71, 0.80) 0.58 (0.47, 0.70) 0.57 (0.36, 0.77) 0.53 (0.38, 0.84) 0.18 (0.07, 0.35)
$\label{eq:constraints} \begin{array}{l} \text{Whetheouse E. et al} \\ \text{ubototal} (l^{k}2=91.14\%, p=0.00) \\ \text{kash} \\ \text{ormenty P et al} \\ \text{isrometti N et al} \\ \text{ubototal} \\ \text{ubototal} \\ \text{ežek Z et al} \\ \text{althan E et al} \\ \text{earned L et al} \\ \text{arned G et al} \\ \text{terez-Duque M} \\ \text{Whetheouse E. et al} \\ \text{whotheouse F. et al} \\ $	210 19 6 32 295 12 8 21 14 215 1057 122 2 2 10	19 54 34 295 12 11 21 27 216 1057 122 19 34 216	← ↓	0.19 (0.09, 0.32) 100 (0.82, 1.00) 0.11 (0.04, 0.23) 0.94 (0.80, 0.99) 100 (0.99, 1.00) 100 (0.74, 1.00) 0.73 (0.39, 0.94) 100 (0.84, 1.00) 0.52 (0.32, 0.71) 100 (0.97, 1.00) 100 (1.00, 1.00) 100 (1.00, 1.00) 0.11 (0.01, 0.33) 0.06 (0.02, 0.06) 0.04 (0.02, 0.07)	Whitehouse E, et al Yrins-Oguneye a, et al Subtotal (P'2 = 97.85%, p = 0.00) Faligue Formenty P et al Giornett IN et al Learned L et al Whitehouse E, et al Subtotal (P'2 = 93.71%, p = 0.00) Sore Throat Giornett IN et al Huha G et al Yrins-Oguneye A et al Subtotal (P'2 = 96.28%, p = 0.00) Difficulty Beathing Formenty P et al Huha G et al Huha G et al	793 61 12 36 1 888 6 21 169 246 45 12 6 15	210 1011 77 19 54 11 1029 54 34 216 325 77 19 34 216		
$\label{eq:constraints} \begin{array}{l} \text{Whitehouse E. et al} \\ \text{ubtotal} (P_2 = 91.14\%, p = 0.00) \\ \text{kash} \\ \text{ormenty P et al} \\ \text{isromethy N et al} \\ \text{ubn G et al} \\ \text{esck 2 et al} \\ \text{athan E et al} \\ \text{earned L et al} \\ \text{farde G et al} \\ \text{farka-Quaye M} \\ \text{Whitehouse E. et al} \\ \text{whotehouse E. et al} \\ whotehous$	210 19 6 32 295 12 8 21 14 215 1057 122 2 2 10	19 54 34 295 12 11 21 21 216 1057 122 19 34 216	+ - +	0.19 (0.09, 0.32) 	$\label{eq:constraints} \begin{array}{l} Whitehouse E, et al \\ Yrins-Ogunkeye A, et al \\ Subtotal (P'2 = 57.85%, p = 0.00) \\ \hline Fatgue \\ Formenty P et al \\ Girometti N et al \\ Learned L et al \\ Whitehouse E et al \\ Subtotal (P'2 = 53.71\%, p = 0.00) \\ \hline Sore Throat \\ Girometti N et al \\ Huhn G et al \\ Whitehouse E, et a$	793 61 12 36 1 888 6 21 169 246 45 12 6 15	216 1011 77 54 11 1029 54 324 216 325 77 19 34 216		 0.76 (0.76, 0.81) 0.77 (0.56, 0.81) 0.79 (0.56, 0.83) 0.50 (0.25, 0.79) 0.50 (0.25, 0.79) 0.99 (0.00, 0.41) 0.86 (0.84, 0.83) 0.86 (0.84, 0.83) 0.86 (0.84, 0.83) 0.86 (0.32, 0.84) 0.76 (0.71, 0.84) 0.76 (0.77, 0.36, 0.77) 0.63 (0.38, 0.84) 0.18 (0.07, 0.35) 0.07 (0.04, 0.11) 0.25 (0.3, 0.54)
Whitehouse E. et al uubtotal (%2 = 91.14%, p = 0.00) tash ormenty P et al ormenty P et al ormenty P et al thun G et al ezek Z et al athane G et al erez-Duque M Witman P et al Whitehouse E. et al Mina-Ogunipes Aet al uubtotal (%2 = 97.32%, p = 0.00) Warrhea ormenty P et al Uubtotal (%2 = %, p = .) Yough Ormenty P et al	210 19 6 32 295 12 8 21 14 215 1057 122 2 10 10	19 54 34 295 12 11 21 27 216 1057 122 19 34 216	← ↓	0.19 (0.09, 0.32) 100 (0.82, 1.00) 0.11 (0.04, 0.23) 0.94 (0.80, 0.99) 100 (0.99, 1.00) 100 (0.74, 1.00) 0.73 (0.39, 0.94) 100 (0.84, 1.00) 0.52 (0.32, 0.71) 100 (0.97, 1.00) 100 (1.00, 1.00) 100 (0.97, 1.00) 0.33 (0.80, 1.00) 0.11 (0.01, 0.33) 0.05 (0.02, 0.05) 0.44 (0.02, 0.07) 0.53 (0.29, 0.75)	Whitehouse E, et al Yrins-Oguneye A, et al Subtotal (P'2 = 97.85%, p = 0.00) Faligue Formenty P et al Giometh H et al Learned L et al Whitehouse E, et al Subtotal (P'2 = 93.71%, p = 0.00) Sore Throat Giometh H et al Huhn G et al Pittman P et al Subtotal (P'2 = 96.20%, p = 0.00) Difficulty Breathing Formenty P et al Huhn G et al Subtotal (P'2 = 96.20%, p = 0.00)	793 61 12 36 1 888 6 21 169 246 45 245 45 12 6 15	216 1011 77 19 54 11 1029 54 34 216		 0.76 (0.76, 0.81) 0.77 (0.68, 0.83) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.79) 0.66 (0.32, 0.85) 0.60 (0.32, 0.85) 0.61 (0.32, 0.85) 0.76 (0.71, 0.80) 0.53 (0.38, 0.84) 0.57 (0.37, 0.84) 0.57 (0.36, 0.77) 0.63 (0.38, 0.84) 0.61 (0.32, 0.85)
Whitehouse E. et al ubtotal ($h2 = 91.14\%$, $p = 0.00$) kash ormenty P et al ormenty P et al whitehouse L et al earned L et al earned L et al fande G et al fande G et al fande G et al finka-Oguniye A et al ubtotal ($h2 = 97.32\%$, $p = 0.00$) biarrhea ormenty P et al tubtotal ($h2 = 97.32\%$, $p = 0.00$) biarrhea ormenty P et al tubtotal ($h2 = \%$, $p = .$) bough	210 19 6 32 295 12 8 21 14 215 1057 122 2 2 10	19 54 34 295 12 11 21 21 21 21 21 21 21 1057 122 19 34 216	+ - +	0.19 (0.09, 0.32) 	Whitehouse E, et al Yrins-Ogunkeye A et al Subtotal ($t^{12} = 97.85\%$, $p = 0.00$) Fatgue Formenty P et al Gironetti N et al Learned L et al Whitehouse E et al Subtotal ($t^{12} = 93.71\%$, $p = 0.00$) Sore Throat Gironetti N et al Huhn G et al Yrinta-Ogunkeye A et al Subtotal ($t^{12} = 96.25\%$, $p = 0.00$) Difficutly Breathing Formenty P et al Huhn G et al Ptiman P et al Subtotal ($t^{12} = 96.25\%$, $p = 0.00$)	793 61 12 36 1 888 6 21 169 246 45 12 6 15	216 1011 77 19 54 11 1029 54 34 216 325 77 19 34 216		 0.76 (0.76, 0.81) 0.77 (0.56, 0.81) 0.50 (0.25, 0.83) 0.50 (0.25, 0.79) 0.50 (0.25, 0.85) 0.50 (0.22, 0.84) 0.76 (0.71, 0.24, 0.23) 0.57 (0.76, 0.71, 0.25) 0.57 (0.36, 0.77) 0.53 (0.38, 0.84) 0.45 (0.07, 0.35) 0.07 (0.04, 0.11) 0.25 (0.03, 0.58)
Nhihehouse E. et al uubtotal (h² = 91.14%, p = 0.00) tash ormenty P et al ormenty P et al ormenty P et al thun G et al ezek Z et al athane G et al ererz-Duque M Yitman P et al Nhihehouse E. et al Yithman P et al Huhn G et al Yithman P et al Huhn G et al Libun G et al Libun G et al Libun G et al Libun G et al	210 19 6 32 295 12 8 21 14 215 1057 122 2 2 10 10 16 10 16	19 54 34 295 12 11 21 216 1057 122 19 34 216 19 34 216	+ - +	0.19 (0.09, 0.32) 100 (0.82, 1.00) 0.11 (0.04, 0.23) 0.94 (0.80, 0.99) 100 (0.99, 1.00) 100 (0.74, 1.00) 0.73 (0.39, 0.94) 100 (0.84, 1.00) 0.52 (0.32, 0.71) 100 (0.97, 1.00) 100 (1.00, 1.00) 100 (0.97, 1.00) 0.93 (0.80, 1.00) 0.11 (0.01, 0.33) 0.05 (0.02, 0.05) 0.44 (0.02, 0.07) 0.53 (0.29, 0.76) 0.47 (0.30, 0.55) 0.47 (0.50, 0.55) 0	Whitehouse E, et al Yrins-Oguneye A, et al Subtotal (P'2 = 97.85%, p = 0.00) Faligue Formenty P et al Giorneth H et al Learned L et al Whitehouse E, et al Subtotal (P'2 = 92.71%, p = 0.00) Sore Throat Giorneth H et al Hubin G et al Pittman P et al Whitehouse E, et al Yinka-Oguneye A et al Subtotal (P2 = 96.25%, p = 0.00) Difficulty Breathing Formenty P et al Hubin G et al Pittman P et al Subtotal (P2 = %2, p = 0.00) Difficulty Breathing Formenty P et al Nausea and /or vermiting Formenty P et al	793 61 12 36 1 888 6 21 169 246 45 12 6 15	216 1011 77 19 54 11 1029 54 34 216 325 77 19 34 216		 0.76 (0.76, 0.81) 0.77 (0.68, 0.83) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.73) 0.69 (0.00, 0.41) 0.86 (0.84, 0.83) 0.60 (0.32, 0.85) 0.11 (0.04, 0.23) 0.82 (0.44, 0.78) 0.76 (0.71, 0.80) 0.53 (0.38, 0.84) 0.76 (0.77, 0.85) 0.57 (0.36, 0.77) 0.63 (0.38, 0.84) 0.18 (0.07, 0.35) 0.07 (0.04, 0.11) 0.25 (0.03, 0.55) 0.11 (0.01, 0.33)
$\label{eq:constraints} \begin{array}{l} \text{Whetheouse E. et al} \\ \text{ubtotal } (P_2 = 91.14\%, p = 0.00) \\ \text{kash} \\ \text{ormenty P et al} \\ \text{isromethy N et al} \\ \text{uhn G et al} \\ \text{eack 2 et al} \\ \text{athan E et al} \\ \text{earned L et al} \\ \text{farked G et al} \\ \text{farked Quue M} \\ \text{Whitehouse E. et al} \\ \text{inka-Ogunleye A et al} \\ \text{ubtotal } (P_2 = 97.32\%, p = 0.00) \\ \text{iarrhea} \\ \text{ormenty P et al} \\ \text{ubtotal } (P_2 = \%, p = .) \\ \text{sough} \\ \text{ormenty P et al} \\ \text{ubtn G et al} \\ \text{eack 2 et al} \\ \text{eack 2 et al} \\ \end{array}$	210 19 6 32 295 12 8 21 14 215 1057 122 2 2 10 10 10 10 10 10 10 10	19 54 34 295 12 11 21 216 1057 122 19 34 216 1057 122	+ - +	0.19 (0.09, 0.32) 	Whitehouse E, et al Yrins-Oguneye A, et al Subtotal ($t^{12} = 97.85\%$, $p = 0.00$) Fatgue Formenty P et al Gioromit N et al Learned L et al Whitehouse E et al Subtotal ($t^{12} = 93.71\%$, $p = 0.00$) Sore Throat Gioromit N et al Hutho G et al Pfitman P et al Subtotal ($t^{12} = 96.26\%$, $p = 0.00$) Difficutly Breathing Formenty P et al Huthon G et al Pfitman P et al Subtotal ($t^{12} = 96.26\%$, $p = 0.00$)	793 61 12 36 1 888 6 21 169 45 12 6 15 12 11	216 19 54 11 1029 54 34 216 325 77 19 34 216 19 34		0.76 (0.76, 0.81) 0.76 (0.76, 0.81) 0.77 (0.56, 0.81) 0.50 (0.25, 0.25) 0.50 (0.25, 0.25) 0.50 (0.25, 0.25) 0.50 (0.25, 0.25) 0.11 (0.04, 0.23) 0.57 (0.72, 0.84) 0.76 (0.71, 0.80) 0.57 (0.36, 0.77) 0.53 (0.38, 0.84) 0.53 (0.38, 0.84) 0.53 (0.38, 0.84) 0.53 (0.38, 0.84) 0.53 (0.38, 0.85) 0.71 (0.01, 0.33) 0.22 (0.17, 0.51)
Nhihehouse E. et al uubtotal (h² = 91.14%, p = 0.00) kash ormenty P et al ormenty P et al aithan E et al aeraed L et al aeraed L et al tande G et al Yhihehouse E. et al Nhihehouse E. et al Yhihehouse E. et al	210 19 6 32 295 12 8 21 14 215 1057 122 2 10 10 10 100 1004	19 54 34 295 12 11 21 216 1057 122 19 34 216 19 34 226	+ - +	0.19 (0.09, 0.32) 100 (0.82, 1.00) 0.11 (0.04, 0.23) 0.94 (0.80, 0.99) 100 (0.99, 1.00) 100 (0.74, 1.00) 0.73 (0.39, 0.94) 100 (0.74, 1.00) 0.52 (0.32, 0.71) 100 (0.97, 1.00) 100 (1.00, 1.00) 100 (0.97, 1.00) 0.93 (0.80, 1.00) 0.11 (0.01, 0.33) 0.05 (0.02, 0.05) 0.44 (0.02, 0.07) 0.53 (0.29, 0.76) 0.47 (0.30, 0.65) 0.36 (0.30, 0.42) 0.44 (0.41, 0.55)	Whitehouse E, et al Yrins-Ogunkye A, et al Subtotal (P'2 = 97.85%, p = 0.00) Faligue Formenty P et al Giorneth H et al Learned L et al Whitehouse E, et al Subtotal (P'2 = 93.71%, p = 0.00) Sore Throat Giorneth H et al Hubin G et al Phiman P et al Whitehouse E, et al Yinka-Ogunkye A et al Subtotal (P'2 = 96.25%, p = 0.00) Difficulty Breathing Pormenty P et al Hubin G et al Pittman P et al Subtotal (P'2 = %, p =) Nausea and /or vomiting Formenty P et al Hubin G et al Pottman P et al Pottman P et al	793 61 12 36 1 8888 6 21 169 246 45 21 169 246 45 15 2 11 23	216 219 54 11 1029 54 216 325 77 77 9 34 216 9 34 2216		 0.76 (0.76, 0.81) 0.77 (0.68, 0.81) 0.79 (0.68, 0.85) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.66 (0.32, 0.85) 0.66 (0.32, 0.85) 0.66 (0.32, 0.85) 0.11 (0.04, 0.23) 0.52 (0.44, 0.76) 0.76 (0.71, 0.80) 0.58 (0.47, 0.70) 0.57 (0.35, 0.84) 0.63 (0.38, 0.84) 0.18 (0.07, 0.35) 0.07 (0.04, 0.11) 0.25 (0.04, 0.73) 0.25 (0.03, 0.58) 0.11 (0.01, 0.33) 0.22 (0.17, 0.51)
$\label{eq:constraints} \begin{array}{llllllllllllllllllllllllllllllllllll$	210 19 6 32 295 12 8 21 14 215 1057 1057 1057 101 106 100 104 5561	19 54 34 295 12 11 21 21 21 21 21 21 21 21 21 21 34 216 1024	+ - + * *	0.19 (0.09, 0.32) → 100 (0.82, 100) 0.11 (0.04, 0.23) → 0.94 (0.80, 0.99) → 100 (0.99, 100) → 100 (0.74, 100) → 0.00 (0.94, 100) → 0.00 (0.97, 100) → 100 (0.97, 100) → 100 (0.97, 100) → 100 (0.97, 100) → 0.93 (0.80, 100) → 0.93 (0.80, 100) → 0.53 (0.22, 0.05) 0.47 (0.30, 0.65) 0.36 (0.30, 0.42) 0.45 (0.52, 0.58) → 0.55 (0.52, 0.58)	Whitehouse E, et al Yrika-Ogunkeş A et al Subtotal ($t^{-2} = 97.85\%$, $p = 0.00$) Fatgue Formenty P et al Giornetti N et al Learned L et al Whitehouse E et al Subtotal ($t^{-2} = 93.71\%$, $p = 0.00$) Sore Throad Giornetti N et al Hutho G et al Pittman P et al Whitehouse E, et al Subtotal ($t^{-2} = 95.20\%$, $p = 0.00$) Difficulty Breathing Formenty P et al Hutho G et al Pittman P et al Subtotal ($t^{-2} = 95.20\%$, $p = 0.00$)	793 61 12 36 1 888 6 21 169 246 45 15 12 6 15 21 12 3 22 11 23 250	216 1011 77 9 54 11 1029 54 216 325 77 19 34 216 34 216 325 77 19 34 216 324 216 325 77		 0.76 (0.76, 0.81) 0.77 (0.68, 0.81) 0.79 (0.68, 0.83) 0.50 (0.25, 0.73) 0.50 (0.25, 0.73) 0.99 (0.00, 0.41) 0.56 (0.34, 0.83) 0.50 (0.32, 0.85) 0.50 (0.32, 0.85) 0.50 (0.32, 0.85) 0.50 (0.32, 0.85) 0.53 (0.33, 0.84) 0.56 (0.44, 0.73) 0.57 (0.72, 0.84) 0.56 (0.44, 0.73) 0.57 (0.33, 0.84) 0.18 (0.07, 0.35) 0.71 (0.04, 0.11) 0.25 (0.33, 0.55) 0.71 (0.01, 0.33) 0.32 (0.17, 0.51) 0.11 (0.01, 0.33) 0.25 (0.22, 0.28)
$\label{eq:second} \begin{tabular}{lllllllllllllllllllllllllllllllllll$	210 19 6 32 2255 12 8 21 14 1057 122 2 2 10 10 16 100 104 561	19 54 34 295 12 11 21 27 216 1057 122 19 34 216 19 34 216 19 34 226 1024	+ - + + *	0.19 (0.09, 0.32) 100 (0.82, 1.00) 0.11 (0.04, 0.23) 0.94 (0.80, 0.99) 100 (0.99, 1.00) 0.73 (0.39, 0.94) 100 (0.84, 1.00) 0.52 (0.32, 0.71) 100 (0.97, 1.00) 100 (0.97, 1.00) 0.93 (0.80, 1.00) 0.93 (0.80, 1.00) 0.11 (0.01, 0.33) 0.05 (0.02, 0.06) 0.04 (0.02, 0.07) 0.53 (0.29, 0.76) 0.47 (0.30, 0.65) 0.48 (0.41, 0.55) 0.55 (0.52, 0.58) 0.47 (0.38, 0.57)	$\label{eq:constraints} \begin{array}{c} \mbox{Whitehouse E, et al} \\ \mbox{Yriss-Oguneye a, et al} \\ \mbox{Yriss-Oguneye A et al} \\ \mbox{Subtal} (P'2 = 97.85\%, p = 0.00) \\ \hline \mbox{Falgue} \\ \mbox{Formenty P et al} \\ \mbox{Ginometin H et al} \\ \mbox{Vintehouse E, et al} \\ \mbox{Yriss-Oguneye A et al} \\ \mbox{Vintehouse E, et al} \\ \mbox{Vintehouse P et al} \\ \mbox{Human P et al} \\ \mbox{Subtal} (P'2 = %5.25\%, p = 0.00) \\ \hline \mbox{Difficulty Getathing} \\ \mbox{Formenty P et al} \\ \mbox{Human P et al} \\ \mbox{Subtal} (P'2 = \%5, p = .) \\ \hline \mbox{Nausea and for vormling} \\ \mbox{Formenty P et al} \\ \mbox{Hum P et al} \\ \mbox{Vintehouse E, et al} \\ Vinteho$	793 61 12 36 1 8883 6 21 169 246 45 6 15 15 2 11 23 250	216 1011 77 19 54 11 1029 54 216 325 77 19 34 216 1010	◊••+ [†] ([†] + [†] [†] [†] [†] [†]	 0.76 (0.76, 0.81) 0.77 (0.68, 0.81) 0.79 (0.68, 0.83) 0.50 (0.25, 0.75) 0.50 (0.25, 0.75) 0.60 (0.32, 0.84) 0.67 (0.53, 0.84) 0.60 (0.32, 0.85) 0.11 (0.04, 0.23) 0.52 (0.44, 0.78) 0.76 (0.71, 0.80) 0.58 (0.47, 0.70) 0.57 (0.36, 0.77) 0.53 (0.38, 0.84) 0.16 (0.07, 0.35) 0.07 (0.04, 0.11) 0.25 (0.03, 0.53) 0.11 (0.04, 0.53) 0.11 (0.04, 0.53) 0.11 (0.07, 0.16) 0.25 (0.22, 0.23)
$\label{eq:constraints} \begin{array}{l} (hitehouse E, et al \math in the set of the set$	210 19 6 32 2255 12 8 211 14 1057 122 2 10 10 10 10 104 551	19 54 34 225 12 27 216 1057 122 11 1057 122 19 34 216 19 34 220 216 1024	+ + + *	0.19 (0.09, 0.32) 100 (0.82, 1.00) 0.11 (0.04, 0.23) 0.94 (0.80, 0.99) 100 (0.99, 1.00) 100 (0.74, 1.00) 0.73 (0.33, 0.94) 100 (0.74, 1.00) 0.52 (0.32, 0.71) 100 (0.97, 1.00) 100 (1.00, 1.00) 100 (1.00, 1.00) 0.93 (0.80, 1.00) 0.93 (0.80, 1.00) 0.11 (0.01, 0.33) 0.05 (0.01, 0.20) 0.05 (0.02, 0.06) 0.44 (0.02, 0.07) 0.53 (0.29, 0.76) 0.47 (0.30, 0.65) 0.55 (0.52, 0.58) 0.47 (0.38, 0.57)	Whitehouse E, et al Yinka-Ogunkeya A, et al Subtotal (P ² = 97.85%, p = 0.00) Patigue Formenty P et al Griometh H et al Learned L et al Whitehouse E, et al Subtotal (P ² = 93.71%, p = 0.00) Griometh H et al Huhn G et al Pitman P et al Subtotal (P ² = 96.25%, p = 0.00) Difficulty Breathing Pomenty P et al Huhn G et al Pitman P et al Subtotal (P ² = %, p = .) Nausea and /or vomiling Formenty P et al Huhn G et al Pitman P et al Subtotal (P ² = %, p = .)	793 61 12 36 1 888 6 21 169 246 45 12 6 15 2 2 11 23 250	216 1011 77 19 54 11 1029 54 216 325 77 19 34 216 1010		 0.76 (0.76, 6.81) 0.77 (0.68, 0.81) 0.79 (0.68, 0.85) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.64) 0.66 (0.32, 0.85) 0.11 (0.04, 0.76) 0.76 (0.71, 0.80) 0.53 (0.38, 0.84) 0.76 (0.71, 0.80) 0.58 (0.47, 0.70) 0.58 (0.47, 0.70) 0.55 (0.38, 0.84) 0.76 (0.71, 0.80) 0.58 (0.77, 0.55) 0.07 (0.04, 0.11) 0.25 (0.03, 0.58) 0.11 (0.01, 0.33) 0.22 (0.17, 0.51) 0.25 (0.22, 0.23) 0.19 (0.09, 0.30)
$\label{eq:constraints} \begin{array}{l} (hitehouse E, et al \mbox{ ubtotal } (h^2 = 91,14\%, p = 0.00) \\ \mbox{ lash } & \mbox{ ormenty P et al } \\ \mbox{ irrometry P et al } \\ \mbox{ ubtotal } et al \\ \mbox{ earned L et al } \\ \mbox{ atmax P et al } \\ \mbox{ itmax P et al } \\ \mbox{ ubtotal } (h^2 = 97,32\%, p = 0.00) \\ \mbox{ iarrhea } \\ \mbox{ ormenty P et al } \\ \mbox{ ubtotal } (h^2 = 87,95\%, p = 0.00) \\ \mbox{ iszek Z et al } \\ \mbox{ itmax P et al } \\ \mbox{ itmax P et al } \\ \mbox{ itmax P et al } \\ \mbox{ ubtotal } (h^2 = 87,95\%, p = 0.00) \\ \mbox{ iszek Z et al } \\ \mbox{ itmax P et al } \\ \mbox{ ubtotal } (h^2 = 87,95\%, p = 0.00) \\ ubtot$	210 19 6 32 295 12 2 8 21 14 215 1057 12 2 2 10 10 10 10 10 10 10 561	19 54 34 225 12 21 21 21 21 21 21 216 1057 122 19 34 216 19 34 216 1024		0.19 (0.09, 0.32) 100 (0.82, 1.00) 0.11 (0.04, 0.23) 0.94 (0.80, 0.99) 100 (0.99, 1.00) 100 (0.74, 1.00) 0.73 (0.39, 0.94) 100 (0.74, 1.00) 0.52 (0.32, 0.71) 100 (0.97, 1.00) 100 (1.00, 1.00) 100 (1.00, 1.00) 0.93 (0.80, 1.00) 0.11 (0.01, 0.33) 0.05 (0.01, 0.20) 0.53 (0.29, 0.76) 0.47 (0.30, 0.65) 0.36 (0.30, 0.42) 0.47 (0.30, 0.65) 0.55 (0.52, 0.58) 0.47 (0.38, 0.57)	Whitehouse E, et al Yinks-Oguneye A, et al Subtotal (P ² = 97.85%, p = 0.00) Faligue Formenty P et al Giometh H et al Learned L et al Whitehouse E, et al Subtotal (P ² = 93.71%, p = 0.00) Sore Throad Giometh H et al Huhn G et al Pitman P et al Subtotal (P ² = 96.25%, p = 0.00) Difficulty Breathing Pomenty P et al Huhn G et al Pitman P et al Subtotal (P ² = %, p = .) Nausea and /or verniling Formenty P et al Huhn G et al Pitman P et al Subtotal (P ² = %, p = .)	793 61 12 36 1 888 6 21 888 6 21 16 9 246 45 12 6 15 2 11 23 250	216 1011 77 54 11 1029 54 216 325 77 19 34 216 19 34 216 19 34 216 1010		 0.76 (0.76, 0.81) 0.77 (0.68, 0.81) 0.79 (0.68, 0.85) 0.50 (0.25, 0.75) 0.63 (0.38, 0.84) 0.67 (0.53, 0.64) 0.66 (0.32, 0.85) 0.11 (0.04, 0.23) 0.52 (0.44, 0.76) 0.76 (0.71, 0.80) 0.58 (0.77, 0.51) 0.58 (0.77, 0.55) 0.77 (0.38, 0.84) 0.11 (0.04, 0.23) 0.25 (0.32, 0.35) 0.11 (0.01, 0.33) 0.22 (0.77, 0.51) 0.11 (0.01, 0.33) 0.25 (0.22, 0.28) 0.19 (0.09, 0.30)
whitehouse E. et al ubtotal ($h^2 = 91.14\%$, $p = 0.00$) kash ormenty P et al jornenti N et al ubn G et al dek Z et al adhan E et al earned L et al earned L et al trima P et al Whitehouse E. et al inka-Quanleye A et al Whitehouse E. et al inka-Quanleye A et al inka-Quanleye B et al inka et al ezek Z et al itman P et al Whitehouse E. et al ubtotal ($h^2 = 87.95\%$, $p = 0.00$)	210 19 6 32 295 12 8 215 1057 122 2 10 10 10 10 10 10 10 10 10 10	19 54 295 12 11 21 216 1057 122 19 34 216 19 34 216 1024		0.19 (0.09, 0.32) → 100 (0.82, 100) 0.11 (0.04, 0.23) → 0.94 (0.80, 0.99) → 100 (0.99, 100) → 100 (0.74, 100) → 0.00 (0.97, 100) → 100 (0.84, 100) 0.52 (0.32, 0.71) → 100 (0.97, 100) → 100 (0.97, 100) → 0.93 (0.80, 100) → 0.93 (0.80, 100) → 0.53 (0.22, 0.05) 0.54 (0.22, 0.05) 0.54 (0.24, 0.25) 0.55 (0.52, 0.55) 0.55 (0.52, 0.58) 0.47 (0.38, 0.57) → 100 (0.97, 100) → 0.11 (0.01, 0.33) 0.05 (0.02, 0.09) 0.04 (0.02, 0.07) → 0.53 (0.29, 0.76) 0.47 (0.38, 0.57) → 0.47 (0.38, 0.57)	Whitehouse E, et al Yrins-Oguneye a, et al Subtotal ($t^{12} = 97.85\%$, $p = 0.00$) Fatigue Formenty P et al Giornetti N et al Learned L et al Whitehouse E, et al Subtotal ($t^{12} = 93.71\%$, $p = 0.00$) Sore Throad Giornetti N et al Huth G et al Ptitman P et al Whitehouse E, et al Subtotal ($t^{12} = 95.25\%$, $p = 0.00$) Difficulty Breathing Formenty P et al Huth G et al Ptitman P et al Subtotal ($t^{12} = 95.25\%$, $p = .)$ Nausea and <i>lor</i> vormling Formenty P et al Huth G et al Ptitman P et al Subtotal ($t^{12} = 95.25\%$, $p = 0.00$)	793 61 12 36 1 888 6 21 189 246 45 246 45 11 23 250	216 1011 77 19 54 11 1029 54 34 216 34 216 19 34 216 19 34 216		 0.76 (0.76, 0.81) 0.77 (0.68, 0.83) 0.79 (0.68, 0.83) 0.50 (0.25, 0.75) 0.63 (0.38, 0.64) 0.67 (0.22, 0.85) 0.60 (0.24, 0.83) 0.60 (0.24, 0.83) 0.60 (0.22, 0.85) 0.60 (0.22, 0.85) 0.60 (0.24, 0.70) 0.55 (0.47, 0.70) 0.57 (0.32, 0.84) 0.76 (0.72, 0.85) 0.71 (0.04, 0.11) 0.25 (0.03, 0.55) 0.11 (0.01, 0.33) 0.22 (0.17, 0.51) 0.11 (0.01, 0.33) 0.25 (0.23, 0.30)

[17]. Nevertheless, as discussed, genitals and even the oral cavity (in more than a third of patients) should also be explored, looking for lesions. Recently, a call was made not only for physicians but for dental surgeons to assess monkeypox as a differential and possible diagnosis during the current outbreak [75].

A critical differentiating clinical finding is lymphadenopathy (62%), which is not present in other diseases such as smallpox or varicella [76]. However, even lymphadenopathy does not differ significantly in frequency between Africans and Europeans, and probably across

Author	n	N		ES (95% CI)	Author	n	N		ES (95% CI)
Monomorphic					Entire Body				
Huhn G et.al	21	31		0.68 (0.49, 0.83)	Ecomenty P et al	8	11		0 73 (0 39 0 94)
Ježek Z et.al	233	295	-	0.79 (0.74, 0.83)	Hube C at al	7	24		0.22 (0.10, 0.11)
Mande G et.al	18	21		0.86 (0.64, 0.97)	Hunn G ecal	/	31		0.23 (0.10, 0.41)
Whitehouse E. et.al	288	319		0.90 (0.86, 0.93)	Subtotal (I^2 = .%, p = .)				0.35 (0.20, 0.50)
Yinka-Ogunleye A et.al	25	40		0.63 (0.46, 0.77)					
Subtotal (1^2 = 85.89%, p = 0.00)			\diamond	0.79 (0.68, 0.88)	Head and/or Neck				
					Formenty P et.al	3	8		0.38 (0.09, 0.76)
Pleomorphic					Girometti N et.al	11	54		0.20 (0.11, 0.34)
Girometti N et.al	48	54		0.89 (0.77, 0.96)	Huhn G et.al	20	32	- _	0.63 (0.44, 0.79)
Huhn G et al	9	31	_	0.29 (0.14, 0.48)	ležek Z et al	258	295	-	0.87 (0.82 0.90)
Ježek Z et al	62	295	+	0.21 (0.17.0.26)	Whitehouse E et al	1038	1057		0.98 (0.97 0.99)
Mande G et al	3	21	_ _	0.14 (0.03, 0.36)	Vicka-Ocupleye A et al	62	71	_	0.06(0.22,0.00)
Vinka-Onunleve A et al	15	40		0.38 (0.23, 0.54)	Cubatel (IAO = 00.072(= = 0.0	00	/1		0.30 (0.88, 0.99)
Subtotal (1^2 = 98 20%, p = 0.00)		10		0.38 (0.12, 0.68)	Subtotal (In2 = 98.07%, p = 0.0	0)			0.74 (0.48, 0.82)
outroits: (i 2 - 00.20 A, p - 0.00)				0.00 (0.12, 0.00)					
Rody Distribution: Contributal					Arms and/or Hands				
Hubn G et al	15	31		0.48 (0.30, 0.67)	Formenty P et.al	3	8	-	0.38 (0.09, 0.76)
latak 7 at al	245	205		0.92 (0.79 0.97)	Girometti N et.al	11	54		0.20 (0.11, 0.34)
	000	1005	-	0.08 (0.05 0.02)	Huhn G et.al	28	32		0.81 (0.64, 0.93)
Subtatal (122 = 96 a =)	808	1025		- 0.90 (0.95, 0.98)	Mande G et al	18	21		- 0.86 (0.64, 0.97)
Subtotal (1~2 = .%, p = .)				0.81 (0.99, 0.90)	Whitehouse E et al	1028	1057	-	0.97 (0.96 0.98)
					Vieks Osuslave A at -1	55	70		0.70 (0.67, 0.97)
Body Distribution: Centripetal			-		Tinka-Oguñleye A et.al	00	/0		0.78 (0.07, 0.87)
Hunn G et.al	1	31	•	0.03 (0.00, 0.17)	Subtotal (I^2 = 97.71%, p = 0.0	U)			0.71 (0.38, 0.95)
Jeżek Z et.al	13	295	•	0.04 (0.02, 0.07)					
Whitehouse E. et.al	33	1025	•	0.03 (0.02, 0.04)	Legs and/or feet				
Subtotal (I^2 = .%, p = .)			•	0.03 (0.02, 0.04)	Formenty P et.al	3	8	-	0.38 (0.09, 0.76)
					Girometti N et.al	11	54	- -	0.20 (0.11, 0.34)
Lesions on Mucous Membranes: 0	Oral Ca	wity			Hubo G et al	21	32		0.66 (0.47 0.81)
Formenty P et.al	6	8		0.75 (0.35, 0.97)	Multicheuro E et al	704	1057		0.74 (0.72, 0.77)
Girometti N et al	4	54	-	0.07 (0.02, 0.18)	vvnitenouse E. et.al	/80	105/	•	0.74 (0.72, 0.77)
Hubo G et al	7	34	_	0 21 (0 09, 0 38)	Yinka-Ogunleye A et.al	63	69	-	0.91 (0.82, 0.97)
Ježek 7 et al	207	295	-	0.70 (0.65, 0.75)	Subtotal (I^2 = 95.43%, p = 0.0	0)			0.61 (0.36, 0.83)
Pittman P et al	53	218		0.25 (0.19, 0.31)					
Whitehouse E et al	570	1018	-	0.58 (0.53, 0.50)	Chest and/or Abdomen				
Subtatal (102 = 07.40% a = 0.00)		1010		0.20 (0.21 0.50)	Girometti N et al	14	54	_ 	0.26 (0.15, 0.40)
Sublota: (1.2 = 87.40%, p = 0.00)				0.38 (0.21, 0.38)	Hubo G et al	18	32	_	0.58 (0.38, 0.74)
					Moltobarras E. et al.	1000	1057	-	
Lesions on Mucous Memoranes: C	Senital	5	_		Vinitenouse E. et.al	1020	1057		0.07 (0.00, 0.00)
Jezek Z et.al	88	280	-	0.30 (0.25, 0.35)	finka-Ogunieye A ecai	50	70		0.80 (0.09, 0.89)
Perez-Duque M	6	27		0.22 (0.09, 0.42)	Subtotal (I^2 = 98.53%, p = 0.0	0)			0.69 (0.28, 0.97)
Whitehouse E. et.al	300	1057	•	0.28 (0.26, 0.31)					
Yinka-Ogunleye A et.al	25	40	_	0.63 (0.46, 0.77)	Pelvic area and groin				
Subtotal (I^2 = 84.48%, p = 0.00)			\sim	0.34 (0.25, 0.44)	Girometti N et.al	51	54		0.94 (0.85, 0.99)
					Huhn G et al	3	32 .		0.09 (0.02, 0.25)
Number of Lesions: >100					Perez-Duque M	6	27	_ _	0.22 (0.09, 0.42)
Breman JG et.al	23	47	_	0.49 (0.34, 0.64)	Whitehourse E at al	200	1057	-	0.22 (0.28 0.21)
Formenty P et.al	3	6		0.50 (0.12, 0.88)	Vvnitenouse E. et.al	300	105/	-	0.28 (0.20, 0.31)
Huhn G et.al	6	30	_ 	0.20 (0.08, 0.39)	Yinka-Ogunieye A et.al	44	65		0.08 (0.55, 0.79)
Ježek Z et.al	218	295	-	0.74 (0.68, 0.79)	Subtotal (I^2 = 97.54%, p = 0.0	0)			0.45 (0.16, 0.76)
Learned L et.al	2	8	-	0.25 (0.03, 0.65)					
Whitehouse F. et al	533	1043		0.51 (0.48, 0.54)	Palms				
Vinka-Opunleye A et al	24	40		0.60 (0.43, 0.75)	Ježek Z et.al	208	295	-	0.70 (0.64, 0.75)
Subtotal /142 = 01 72% c = 0.001				0.50 (0.38, 0.64)	Whitehouse E et al	1009	1057		0.95 (0.94 0.97)
Substate: (1:2 = 01.7270, p = 0.00)				0.00 (0.00, 0.04)	Vicka-Ocupleve A et al	48	70		0.60 (0.56 0.70)
Number of Losions: <100					Cubatal (March et al.	40	10		0.00 (0.50, 0.78)
Parament IC stal	24	47		0.54 (0.38 0.88)	Subtotal (In2 = .%, p = .)				0.80 (0.53, 0.97)
breman JG et.al	24	4/		0.51 (0.36, 0.66)					
Formenty Plet.al	3	9		0.50 (0.12, 0.88)	Sole of the foot				
Huhn G et.al	24	30		- 0.80 (0.61, 0.92)	Ježek Z et.al	196	295	-	0.66 (0.61, 0.72)
Jeżek Z et.al	77	295	+	0.26 (0.21, 0.32)	Mande G et al	15	21		0.71 (0.48, 0.89)
Learned L et.al	6	8		0.75 (0.35, 0.97)	Whitehouse E et al.	885	1057		0.84 (0.81, 0.86)
Whitehouse E. et.al	510	1043	•	0.49 (0.46, 0.52)	Viela Oquelaue A et al	42	88		0.84 (0.61, 0.00)
Yinka-Ogunleye A et.al	16	40		0.40 (0.25, 0.57)	Tinka-Ogunieye A et.al	92	00		0.04 (0.51, 0.75)
Subtotal (I^2 = 91.72%, p = 0.00)			\diamond	0.50 (0.36, 0.64)	Subtotal (In2 = 93.76%, p = 0.0	0)		\sim	0.72 (0.58, 0.84)
				1			1	2 4 6 0	1
			0 .2 .4 .6 .8	1			0	.2 .4 .0 .0	

the years of study, confirming their importance as a clinical finding in monkeypox [77, 78].

Although most patients did not require hospitalisation (65%), multiple complications may occur, ranging from haemorrhagic pustules (1%) to secondary bacterial skin infections (18%), that may lead to fatal outcomes that have occurred among African patients, but even 10% of European patients were hospitalised.

Case-control studies and cohort studies derived from the 2022 outbreak are necessary to better define the disease's clinical evolution. Clinical characterisation by disease phases and correlation with viremia and viral DNA detection in other body fluids is currently key to understanding disease and transmission. More studies are needed to elucidate the risk factors for severe illness and death. That will allow for identifying groups most likely to have poor outcomes so that we can focus on prevention and treatment efforts. It is supposed that very young children, pregnant women [79, 80], elderly and immunocompromised persons are at higher risk of complicated disease, but this needs further assessment [81].

The laboratory abnormalities were not included in this systematic review. There is a lack of studies, more reports are needed, and only a few data are reported in recent case reports [45] and some studies before 2022 [29]. Leukopenia, thrombocytopenia, elevated blood urea nitrogen, increased hepatic transaminases (ALT/AST), and hypoalbuminemia has been reported in the past and is associated with monkeypox disease [29]. In the recent case series in the United Kingdom of imported illness from 2018 to 2021, transaminitis was reported in association with antiviral treatment in three patients using brincidofovir. Antiviral therapy is another gap in available information regarding its use and apparent efficacy and safety as a treatment for monkeypox [46, 82]. Multiple aspects of monkeypox were not addressed before the 2003 United States outbreak [83].

Our results showed that there is still a need for more comprehensive clinical studies, including short- and

Ocular Lesions			
Breman JG et.al	1	47 া	0.02 (0.00, 0.11)
Ježek Z et.al	11	295	0.04 (0.02, 0.07)
Learned L et.al	1	11 -	0.09 (0.00, 0.41)
Mande G et.al	8	21	0.38 (0.18, 0.62)
Pittman P et.al	23	216 🛨	0.11 (0.07, 0.16)
Subtotal (I ² = 84.37%, p = 0.00)		\diamond	0.09 (0.02, 0.18)
Secondary Bacterial Skin infection			
Girometti N et.al	6	54 -	0.11 (0.04, 0.23)
Ježek Z et.al	48	295 -	0.16 (0.12, 0.21)
Pittman P et.al	18	216 🖶	0.08 (0.05, 0.13)
Yinka-Ogunleye A et.al	19	40	0.47 (0.32, 0.64)
Subtotal (1 2 - 80.55 %, p - 0.00)		\checkmark	0.16 (0.00, 0.00)
Hemorrhagic Pustules Huhn G et al	2	34 -	0.06 (0.01, 0.20)
Ježek Z et.al	0	295	0.00 (0.00, 0.01)
Pittman P et.al	6	216	0.03 (0.01, 0.06)
Subtotal (I^2 = .%, p = .)	-	0	0.01 (0.00, 0.07)
Ulcerated or Necrotic Lesions			004/044 0440
Hunn G et.al	8	34	0.24 (0.11, 0.41)
Jezek 2 et.al	0	295	0.00 (0.00, 0.01)
Perez-Duque M	11	2/	0.02 (0.01 0.08)
Subtotal ($1/2 = 05.84\%$ $p = 0.00$)	0	210	0.03 (0.01, 0.03)
Subtata (1 2 - 80.04 M, p - 0.00)			0.10 (0.00, 0.20)
Deaths		_	
Breman JG et.al	8	47	0.17 (0.08, 0.31)
Formenty P et.al	0	19	0.00 (0.00, 0.18)
Hunn G et.al	0	31	0.00 (0.00, 0.11)
Jezek 2 et.al	33	338 -	0.10 (0.07, 0.13)
	0	12	0.00 (0.00, 0.37)
Perez-Duque M	0	27	0.00 (0.00, 0.28)
Pittman P et al	3	216	0.01 (0.00, 0.13)
Yinka-Qounleve A et al	7	122	0.06 (0.02, 0.11)
Subtotal (I ^A 2 = 79.10%, p = 0.00)			0.04 (0.01, 0.09)
Hospitalized Patients			
Formenty P et.al	7	19	0.37 (0.16, 0.62)
Girometti N et.al	5	54 -	0.09 (0.03, 0.20)
Huhn G et.al	7	31	0.23 (0.10, 0.41)
Kalthan E et.al	10	12	0.83 (0.52, 0.98)
Learned L et.al	8	11	0.73 (0.39, 0.94)
Perez-Duque M	3	27 -	0.11 (0.02, 0.29)
Subtotal (I^2 = 87.95%, p = 0.00)		\sim	0.35 (0.14, 0.59)
		1 1	

long-term follow-up cohort assessments. More studies from outside Africa, now that 37 non-endemic countries have reported cases are necessary to contribute to the growing volume of data, in addition to the increasing number of studies appearing in 2022 from African countries [84–86]. Even more, assessing the impact of spreading events, including the pride parties and festivals on Grand Canary island in Spain or Belgium, needs better evaluations [18, 36, 41, 42, 71–73]. More studies are also required from non-European and non-African

countries, including North and Latin America, the Middle East and Oceania, regions already affected by monkeypox [8, 42, 49]. Further clinical data is crucial to elucidate the clinical spectrum of the disease. Up to now, the clinical findings are consistent regardless of report type (cross-sectional studies or case reports). However, more data are needed to define the risk factors for hospitalisation and possible fatal outcomes outside Africa. In other resource-constrained settings, different from Africa, supply chains, including those for drugs, masks and personal protection equipment, will be rechallenged, although at a lower level than COVID-19 [58].

The results of this systematic review highlight the findings that may assist clinicians anywhere in the globe in suspecting the possibility of monkeypox infection in those with recent travel to areas with the ongoing transmission or among contacts of confirmed cases, according to global and national definitions. Early recognition of cases will allow clinicians to ensure adequate clinical monitoring, supportive interventions, and preventing further transmission by implementing infection control measures [1, 2, 31, 67, 73, 87]. There is a need for prospective studies to evaluate the epidemiology, pathogenesis, duration of viral shedding, and the clinical spectrum of disease associated with this zoonotic emerging viral infection [88].

To effectively protect populations and healthcare workers in the face of the arrival and spreading of this emerging viral pathogen, constant evaluation of available evidence is essential to guide clinical suspicion, diagnosis, management and mitigation of transmission of monkeypox.

Limitations

This review has several limitations. First, few studies are available for inclusion. Most are from Africa and Europe. It would be better to include as many studies with a broad geographic scope to understand monkeypox comprehensively. More detailed patient information, particularly regarding clinical outcomes, was unavailable in many studies at the time of analyses; however, the data in this review allow a first synthesis of the clinical characteristics of monkeypox. Finally, possible heterogeneity of the studies included should be considered for different variables. Additionally, we could not identify detailed information from the patients for many variables. In addition, the variability of the populations, including their nationality, origin or belonging to some specific ethnicity and other epidemiological aspects that they could possess, as well as the differences in the designs of the studies reviewed.

Conclusions

Infection with the monkeypox virus is associated with significant cutaneous compromise. Therefore, most patients will not require hospitalisation. Similar to other viral pathogens, monkeypox presents a progressive course of fever in most cases. A significant distinguishing factor includes lymphadenopathy. Eliciting a history of recent travel to areas with ongoing outbreaks of this emerging pathogen or contact with a confirmed case of monkeypox should prompt clinicians to initiate isolation precautions and obtain laboratory confirmation by PCR. Additional research is needed to elucidate viral and host factors in the pathogenesis of severe and fatal infections.

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12941-022-00527-1.

Additional file 1: Table S1. Search strategies. Table S2. Cases Definitions. Table S3. Quality assessment of included studies. Table S4. Analysis of subgroups according to continents. Table S5. Sensitivity analysis according to the risk of bias.

Acknowledgements None.

None.

Author contributions

VBZ, and AJRM, formulated the research questions, designed the study, developed the preliminary search strategy and drafted the manuscript. DKBA, JRUB, EAAB, EAHB, and MDMR refined the search strategy by conducting iterative database queries and incorporating new search terms. JRUB, EAAB, EAHB, MDMR, DBKA, VBZ, and AJRM searched and collected the articles. JRUB, EAAB, EAHB, MDMR, and VBZ conducted the quality assessment. All authors critically reviewed the manuscript for relevant intellectual content. All authors have read and approved the final version of the manuscript.

Funding

The research was financed by the Universidad Peruana de Ciencias Aplicadas through grant A-024-2021.

Declarations

Ethics approval and consent to participate

Approval was not required.

Competing interests

All authors report no potential conflicts, except AJRM. AJRM is Deputy Editorin-Chief of Annals of Clinical Microbiology and Antimicrobials. All authors have submitted the ICMJE Form for Disclosure of Potential.

Author details

¹Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Perú.
²Sociedad Científica de Estudiantes de Medicina de la Universidad Peruana de Ciencias Aplicadas, Lima, Perú.
³Sociedad Científica de Estudiantes de Medicina de la Universidad Nacional de Trujillo, Trujillo, Perú.
⁴Grupo Peruano de Investigación Epidemiológica, Unidad Para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Perú.
⁵Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia.
⁶Latin American

Network of MOnkeypox VIrus Research (LAMOVI), Pereira, Risaralda, Colombia. ⁷Master of Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima, Perú. ⁸Faculty of Medicine, Institución Universitaria Visión de Ias Américas, Pereira, Risaralda, Colombia.

Received: 24 June 2022 Accepted: 1 August 2022 Published online: 10 August 2022

References

- Monkeypox—United Kingdom of Great Britain and Northern Ireland. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON383. Accessed 23 June 2022.
- Monkeypox outbreak toolbox. https://www.who.int/emergencies/outbr eak-toolkit/disease-outbreak-toolboxes/monkeypox-outbreak-toolbox. Accessed 23 June 2022.
- Bleyer JG. Ueber auftreten von variola unter affen der genera mycetes und cebus bei vordringen einer pockenepidemie im urwaldgebiete an den nebenflüssen des alto uruguay in südbrasilien. Muench Med Wochenschr. 1922;69:1009–10.
- Magnus PV, Andersen EK, Petersen KB, Birch-Andersen A. A poxlike disease in cynomolgus monkeys. Acta Pathol Microbiol Scand. 1959;46(2):156–76.
- Heberling RL, Kalter SS. Induction, course, and transmissibility of monkeypox in the baboon (Papio cynocephalus). J Infect Dis. 1971;124(1):33–8.
- Bonilla-Aldana DK, Rodriguez-Morales AJ. Is monkeypox another reemerging viral zoonosis with many animal hosts yet to be defined? Vet Q. 2022;42(1):148–50.
- Farahat RA, Abdelaal A, Shah J, Ghozy S, Sah R, Bonilla-Aldana DK, Rodriguez-Morales AJ, McHugh TD, Leblebicioglu H. Monkeypox outbreaks during COVID-19 pandemic: are we looking at an independent phenomenon or an overlapping pandemic? Ann Clin Microbiol Antimicrob. 2022;21(1):26.
- Basgoz N, Brown CM, Smole SC, Madoff LC, Biddinger PD, Baugh JJ, Shenoy ES. Case 24–2022: a 31-year-old man with perianal and penile ulcers, rectal pain, and rash. N Engl J Med. 2022. https://doi.org/10.1056/NEJMc pc2201244.
- Patrocinio-Jesus R, Peruzzu F. Monkeypox Genital Lesions. N Engl J Med. 2022. https://doi.org/10.1056/NEJMicm2206893.
- Ortiz-Martínez Y, Rodríguez-Morales AJ, Franco-Paredes C, Chastain DB, Gharamti AA, Vargas Barahona L, Henao-Martínez AF. Monkeypox – a description of the clinical progression of skin lesions: a case report from Colorado, USA. Ther Adv Infect Dis. 2022;9:20499361221117730.
- Alakunle E, Moens U, Nchinda G, Okeke MI. Monkeypox virus in Nigeria: infection biology, epidemiology, and evolution. Viruses. 2020. https://doi. org/10.3390/v12111257.
- Doty JB, Malekani JM, Kalemba LN, Stanley WT, Monroe BP, Nakazawa YU, Mauldin MR, Bakambana TL, LiyandjaDjaLiyandja T, Braden ZH, et al. Assessing monkeypox virus prevalence in small mammals at the humananimal interface in the democratic Republic of the Congo. Viruses. 2017. https://doi.org/10.3390/v9100283.
- Nakazawa Y, Mauldin MR, Emerson GL, Reynolds MG, Lash RR, Gao J, Zhao H, Li Y, Muyembe JJ, Kingebeni PM, et al. A phylogeographic investigation of African monkeypox. Viruses. 2015;7(4):2168–84.
- Sood A, Sui Y, McDonough E, Santamaria-Pang A, Al-Kofahi Y, Pang Z, Jahrling PB, Kuhn JH, Ginty F. Comparison of multiplexed immunofluorescence imaging to chromogenic immunohistochemistry of skin biomarkers in response to monkeypox virus infection. Viruses. 2020;12(8):78.
- 15. León-Figueroa DA, Bonilla-Aldana DK, Pachar M, Romaní L, Saldaña-Cumpa HM, Anchay-Zuloeta C, Diaz-Torres M, Franco-Paredes C, Suárez JA, Ramirez JD, et al. The never ending global emergence of viral zoonoses after COVID-19? The rising concern of monkeypox in Europe, North America and beyond. Travel Med Infect Dis. 2022;49: 102362.
- Cohen-Gihon I, Israeli O, Shifman O, Erez N, Melamed S, Paran N, Beth-Din A, Zvi A. Identification and Whole-Genome Sequencing of a Monkeypox Virus Strain Isolated in Israel. Microbiol Resour Announc. 2020. https://doi. org/10.1128/MRA.01524-19.

- Rodriguez-Morales AJ. Monkeypox and the importance of cutaneous manifestations for disease suspicion. Microbes, Infection and Chemotherapy. 2022;2: e1450.
- Bížová B, Veselý D, Trojánek M, Rob F. Coinfection of syphilis and monkeypox in HIV positive man in Prague. Czech Republic Travel Med Infect Dis. 2022. https://doi.org/10.1016/j.tmaid.2022.102368.
- Mileto D, Riva A, Cutrera M, Moschese D, Mancon A, Meroni L, Giacomelli A, Bestetti G, Rizzardini G, Gismondo MR, et al. New challenges in human monkeypox outside Africa: a review and case report from Italy. Travel Med Infect Dis. 2022. https://doi.org/10.1016/j.tmaid.2022.102386.
- Bragazzi NL, Kong JD, Mahroum N, Tsigalou C, Khamisy-Farah R, Converti M, Wu J. Epidemiological trends and clinical features of the ongoing monkeypox epidemic: a preliminary pooled data analysis and literature review. J Med Virol. 2022. https://doi.org/10.1002/jmv.27931.
- Cardona-Ospina JA, Henao-SanMartin V, Acevedo-Mendoza WF, Nasner-Posso KM, Martinez-Pulgarin DF, Restrepo-Lopez A, Valencia-Gallego V, Collins MH, Rodriguez-Morales AJ. Fatal Zika virus infection in the Americas: a systematic review. Int J Infect Dis. 2019;88:49–59.
- 22. Rodriguez-Morales AJ, Cardona-Ospina JA, Fernanda Urbano-Garzon S, Sebastian Hurtado-Zapata J. Prevalence of post-chikungunya infection chronic inflammatory arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2016;68(12):1849–58.
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–12.
- 24. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
- Drevon D, Fursa SR, Malcolm AL. Intercoder Reliability and Validity of Web-PlotDigitizer in Extracting Graphed Data. Behav Modif. 2017;41(2):323–39.
- Barker TH, Migliavaca CB, Stein C, Colpani V, Falavigna M, Aromataris E, Munn Z. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol. 2021;21(1):189.
- Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J Clin Epidemiol. 2014;67(8):897–903.
- Formenty P, Muntasir MO, Damon I, Chowdhary V, Opoka ML, Monimart C, Mutasim EM, Manuguerra JC, Davidson WB, Karem KL, et al. Human monkeypox outbreak caused by novel virus belonging to Congo Basin clade, Sudan, 2005. Emerg Infect Dis. 2010;16(10):1539–45.
- Huhn GD, Bauer AM, Yorita K, Graham MB, Sejvar J, Likos A, Damon IK, Reynolds MG, Kuehnert MJ. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis. 2005;41(12):1742–51.
- Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, Mamadu I, Akinpelu A, Ahmad A, Burga J, et al. Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis. 2019;19(8):872–9.
- Whitehouse ER, Bonwitt J, Hughes CM, Lushima RS, Likafi T, Nguete B, Kabamba J, Monroe B, Doty JB, Nakazawa Y, et al. Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011–2015. J Infect Dis. 2021;223(11):1870–8.
- Jezek Z, Grab B, Szczeniowski M, Paluku KM, Mutombo M. Clinico-epidemiological features of monkeypox patients with an animal or human source of infection. Bull World Health Organ. 1988;66(4):459–64.
- Kalthan E, Dondo-Fongbia JP, Yambele S, Dieu-Creer LR, Zepio R, Pamatika CM. Twelve cases of monkeypox virus outbreak in Bangassou District (Central African Republic) in December 2015. Bull Soc Pathol Exot. 2016;109(5):358–63.
- Pittman PR, Martin JW, Kingebeni PM, Tamfum JJM, Wan Q, Reynolds MG, Quinn X, Norris S, Townsend MB, Satheshkumar PS, et al. Clinical characterization of human monkeypox infections in the Democratic Republic of the Congo. MedRxiv. 2022;46:593.
- 35. Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970–79. Bull World Health Organ. 1980;58(2):165–82.
- 36. Perez Duque M, Ribeiro S, Martins JV, Casaca P, Leite PP, Tavares M, Mansinho K, Duque LM, Fernandes C, Cordeiro R, et al. Ongoing

monkeypox virus outbreak, Portugal, 29 April to 23 May 2022. Euro Surveill. 2022. https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200424.

- Learned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, Karem K, Stempora LL, Braden ZH, Kline R, Likos A, et al. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg. 2005;73(2):428–34.
- Mande G, Akonda I, De Weggheleire A, Brosius I, Liesenborghs L, Bottieau E, Ross N, Gembu G-C, Colebunders R, Verheyen E, et al. Enhanced surveillance of monkeypox in Bas-Uélé, Democratic Republic of Congo: the limitations of symptom-based case definitions. MedRxiv. 2022;32:238.
- Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, ... Epidemiological characteristics and clinical features of confirmed human monkeypox virus cases in individuals attending a sexual health Centre in London paperssrncom.
- Vaughan A, Aarons E, Astbury J, Balasegaram S, Beadsworth M, Beck CR, Chand M, O'Connor C, Dunning J, Ghebrehewet S, et al. Two cases of monkeypox imported to the United Kingdom, September 2018. Euro Surveill. 2018. https://doi.org/10.2807/1560-7917.ES.2018.23.38.18005 09.
- Antinori A, Mazzotta V, Vita S, Carletti F, Tacconi D, Lapini LE, D'Abramo A, Cicalini S, Lapa D, Pittalis S, et al. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Euro Surveill. 2022. https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200421.
- Hammerschlag Y, MacLeod G, Papadakis G, Adan Sanchez A, Druce J, Taiaroa G, Savic I, Mumford J, Roberts J, Caly L, et al. Monkeypox infection presenting as genital rash, Australia, May 2022. Euro Surveill. 2022. https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200411.
- 43. de Nicolas-Ruanes B, Vivancos MJ, Azcarraga-Llobet C, Moreno AM, Rodriguez-Dominguez M, Berna-Rico ED, Garcia-Mouronte E, Carron-Herrero A, McGee A, Galan JC, et al. Monkeypox virus case with maculopapular exanthem and proctitis during the Spanish outbreak in 2022. JEADV. 2022. https://doi.org/10.1111/jdv.18300.
- Reynolds MG, Wauquier N, Li Y, Satheshkumar PS, Kanneh LD, Monroe B, Maikere J, Saffa G, Gonzalez JP, Fair J, et al. Human monkeypox in sierra leone after 44-year absence of reported cases. Emerg Infect Dis. 2019;25(5):1023–5.
- Erez N, Achdout H, Milrot E, Schwartz Y, Wiener-Well Y, Paran N, Politi B, Tamir H, Israely T, Weiss S, et al. Diagnosis of Imported Monkeypox, Israel, 2018. Emerg Infect Dis. 2019;25(5):980–3.
- 46. Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022;22(8):1153–62.
- Hutin YJ, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL, Rodriguez M, Knight JC, Tshioko FK, Khan AS, et al. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis. 2001;7(3):434–8.
- Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, Kazmierczak JJ, Stratman EJ, Li Y, Fairley JA, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med. 2004;350(4):342–50.
- 49. Cimerman S, Chebabo A, Cunha CAD, Barbosa AN, Rodriguez-Morales AJ. Human monkeypox preparedness in Latin America - Are we ready for the next viral zoonotic disease outbreak after COVID-19? Br J Infect Dis. 2022;26(3): 102372.
- Rodriguez-Morales AJ, Lopardo G, Verbanaz S, Orduna T, Lloveras S, Azeñas-Burgoa JM, Escalera-Antezana JP, Alvarado-Arnez LE, Barbosa AN, Diaz-Quijano F, et al. Latin America: Situation and preparedness facing the multi-country human monkeypox outbreak. Lancet Regional Health Am. 2022;13: 100318.
- Rodriguez-Morales AJ, Lopardo G. Monkeypox: another sexually transmitted infection? Pathogens. 2022;11(7):713.
- Zambrano PG, Acosta-España JD, Mosquera Moyano F, Altamirano Jara MB. Sexually or intimately transmitted infections: A look at the current outbreak of monkeypox in 2022. Travel Med Infect Dis. 2022. https:// doi.org/10.1016/j.tmaid.2022.102383.
- Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA. 2020. https://doi.org/10.1001/jama.2020. 0757.

- Cimerman S, Chebabo A, Cunha CAD, Rodríguez-Morales AJ. Deep impact of COVID-19 in the healthcare of Latin America: the case of Brazil. Br J Infect Dis. 2020;24(2):93–5.
- 55. Cimerman S, Chebabo A, Cunha CAD, Rodríguez-Morales AJ. One year after the arrival of COVID-19 in Latin America: what have we learned in Brazil and other countries? Br J Infect Dis. 2021;25(2): 101571.
- Ihekweazu C, Yinka-Ogunleye A, Lule S, Ibrahim A. Importance of epidemiological research of monkeypox: is incidence increasing? Expert Rev Anti Infect Ther. 2020;18(5):389–92.
- Rodriguez-Morales AJ, Cardona-Ospina JA, Collins MH. Emerging and re-emerging vector-borne and zoonotic diseases. Front Med. 2021;8: 714630.
- Rodriguez-Morales AJ, Paniz-Mondolfi AE, Faccini-Martínez ÁA, Henao-Martínez AF, Ruiz-Saenz J, Martinez-Gutierrez M, Alvarado-Arnez LE, Gomez-Marin JE, Bueno-Marí R, Carrero Y, et al. The constant threat of zoonotic and vector-borne emerging tropical diseases: living on the edge. Front Trop Dis. 2021;2: 676905.
- Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, Méndez CA, Zambrano LI, Franco-Paredes C, Suárez JA, Rodriguez-Enciso HD, Balbin-Ramon GJ, Savio-Larriera E, et al. COVID-19 in Latin America: the implications of the first confirmed case in Brazil. Travel Med Infect Dis. 2020;35: 101613.
- Rudan I. The COVID-19 pandemic: SARS-CoV-2, childhood hepatitis and monkeypox raise five new questions for the global health research community. J Glob Health. 2022;22:01002.
- Kozlov M. Monkeypox outbreaks: 4 key questions researchers have. Nature. 2022;606(7913):238–9.
- 62. Kupferschmidt K. Monkeypox vaccination plans take shape amid questions. Science (New York, NY). 2022;376(6598):1142–3.
- 63. Costello V, Sowash M, Gaur A, Cardis M, Pasieka H, Wortmann G, Ramdeen S. Imported Monkeypox from International Traveler, Maryland, USA, 2021. Emerg Infect Dis. 2022;28(5):1002–5.
- Hobson G, Adamson J, Adler H, Firth R, Gould S, Houlihan C, Johnson C, Porter D, Rampling T, Ratcliffe L, et al. Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021. Euro Surveill. 2021. https://doi.org/10.2807/1560-7917.ES.2021.26.32. 2100745.
- Kyaw WM, Vasoo S, Ho HJA, Chan M, Yeo TW, Manauis CM, Ang H, De Pratim P, Ang BSP, Chow ALP. Monitoring healthcare professionals after monkeypox exposure: experience from the first case imported to Asia. Infect Control Hosp Epidemiol. 2020;41(3):373–5.
- Yong SEF, Ng OT, Ho ZJM, Mak TM, Marimuthu K, Vasoo S, Yeo TW, Ng YK, Cui L, Ferdous Z, et al. Imported Monkeypox, Singapore. Emerg Infect Dis. 2020;26(8):1826–30.
- Clinical management and infection prevention and control for monkeypox: Interim rapid response guidance, 2022. https://www.who.int/publi cations/i/item/WHO-MPX-Clinical-and-IPC-2022.1. Accessed 10 Jun 2022.
- Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, Steffen R. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2): e0010141.
- Paniz-Mondolfi AE, Rodriguez-Morales AJ, Blohm G, Marquez M, Villamil-Gomez WE. ChikDenMaZika Syndrome: the challenge of diagnosing arboviral infections in the midst of concurrent epidemics. Ann Clin Microbiol Antimicrob. 2016;15(1):42.
- 70. Bhunu CP, Mushayabasa S, Hyman JM. Modelling HIV/AIDS and monkeypox co-infection. Appl Math Comput. 2012;218(18):9504–18.
- Kluge H, Ammon A. Monkeypox in Europe and beyond—tackling a neglected disease together. Euro Surveill. 2022. https://doi.org/10.2807/ 1560-7917.ES.2022.27.24.2200482.
- Miura F, van Ewijk CE, Backer JA, Xiridou M, Franz E, Op de Coul E, Brandwagt D, van Cleef B, van Rijckevorsel G, Swaan C et al: Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022. Euro Surveill 2022. https://doi.org/10.2807/1560-7917.ES.2022. 27.24.2200448
- Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, Brown CS, Chow Y, Edeghere O, Florence I, et al. Community transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill. 2022. https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200422.
- Ortiz-Martínez Y, Zambrano-Sanchez G, Rodríguez-Morales AJ. Monkeypox and HIV/AIDS: When the outbreak faces the epidemic. Int J STD AIDS. 2022. https://doi.org/10.1177/09564624221114191.

- 75. Murphy S. Monkeypox. Br Dent J. 2022;232(11):760.
- McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis. 2014;58(2):260–7.
- Saxena SK, Ansari S, Maurya VK, Kumar S, Jain A, Paweska JT, Tripathi AK, Abdel-Moneim AS. Re-emerging human monkeypox: a major publichealth debacle. J Med Virol. 2022. https://doi.org/10.1002/jmv.27902.
- Quarleri J, Delpino MV, Galvan V. Monkeypox: considerations for the understanding and containment of the current outbreak in nonendemic countries. GeroScience. 2022. https://doi.org/10.1007/ s11357-022-00611-6.
- Dashraath P, Nielsen-Saines K, Mattar C, Musso D, Tambyah P, Baud D. Guidelines for pregnant individuals with monkeypox virus exposure. Lancet. 2022. https://doi.org/10.1016/S0140-6736(22)01063-7.
- Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P, Rimoin AW, Martin JW, Muyembe JT. Maternal and fetal outcomes among pregnant women with human monkeypox infection in the democratic Republic of Congo. J Infect Dis. 2017;216(7):824–8.
- European Centers for Disease Control and Prevention (ECDC): Monkeypox multi-country outbreak—apid risk assessment; 2022. https://www. ecdc.europa.eu/en/publications-data/risk-assessment-monkeypox-multicountry-outbreak. Accessed 23 June 2022.
- Hutson CL, Kondas AV, Mauldin MR, Doty JB, Grossi IM, Morgan CN, Ostergaard SD, Hughes CM, Nakazawa Y, Kling C, et al. Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model. MSphere. 2021. https://doi.org/10.1128/ mSphere.00126-21.
- Rodríguez-Morales AJ, Ortiz-Martínez Y, Bonilla-Aldana DK. What has been researched about Monkeypox? A bibliometric analysis of an old zoonotic virus causing global concern. New Microbes New Infect. 2022;47:100993. https://doi.org/10.1016/j.nmni.2022.100993.
- Amao LK, Olatunji DI, Igbodo G, Okoli SC, Amaechi I, Goni MI, Ehiakhamen O, Aderinola O, Ogunleye A, Ogunbode O, et al. Trend and enhanced surveillance of Monkeypox during COVID-19 pandemic in Nigeria. J Public Health Afr. 2022;13(1):2184.
- Eseigbe EE, Akude C, Osagie IA, Eseigbe P. Human monkey pox virus infection in plateau state, north central nigeria: a report of two cases. West Afr J Med. 2021;38(12):1242–6.
- Guagliardo SAJ, Monroe B, Moundjoa C, Athanase A, Okpu G, Burgado J, Townsend MB, Satheshkumar PS, Epperson S, Doty JB, et al. Asymptomatic orthopoxvirus circulation in humans in the wake of a monkeypox outbreak among chimpanzees in cameroon. Am J Trop Med Hyg. 2020;102(1):206–12.
- Ortiz-Martínez Y, Galvis-Cataño LM, Arias-Rodríguez D, Romero-Dager C, Bonilla-Aldana DK, Rodriguez-Morales AJ. YouTube and 2022 Monkeypox outbreak: opportunities for awareness and infection control. J Hosp Infect. 2022. https://doi.org/10.1016/j.jhin.2022.07.007.
- Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A, Reeves I, Habibi MS, et al. Monkeypox Virus Infection in Humans across 16 Countries—April-June 2022. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2207323.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

